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Abstract
ABSTRACT
Abigail J. Christian
Robert J. Levy
Harry Ischiropoulos
Bioprosthetic heart valves (BHV) are widely used in interventions for symptomatic valvular disease;
however, they begin to fail clinically after 10 years, most frequently due to structural deterioration.
Calcification has been considered the major mechanism of BHV degeneration although other
mechanisms may be involved. In this work, we investigated the hypothesis that oxidants contribute to
BHV structural degeneration. BHV have been shown to elicit an inflammatory response from the patient,
thereby resulting in the production of reactive oxygen and reactive nitrogen species which may degrade
BHV. To determine the role of oxidants in BHV degeneration, we analyzed clinically failed BHV explants for
markers of oxidation and utilized experimental systems to identify the consequences of BHV oxidation.
Clinical BHV explants were found to have elevated levels of the tyrosine oxidation product dityrosine,
therefore indicating that BHV are susceptible to oxidation. Exposure of the BHV material glutaraldehydefixed bovine pericardium (BP) to oxidizing conditions demonstrated that oxidation of BHV results in the
loss of glutaraldehyde cross-links, disruption of the collagen structure, and an increase in susceptibility to
proteolytic degradation. To address this mechanism of BHV structural degeneration, we developed two
antioxidant delivery strategies. Our first approach involved covalent immobilization of the oxidant
scavenger 3-(4-hydroxy-3,5-di-tert-butylphenyl) propyl amine (DBP) to BHV leaflet materials whereas the
second method utilized passive incorporation of a catalytic antioxidant, a superoxide dismutase (SOD)
mimetic, into the material. Both strategies demonstrated efficient delivery of an antioxidant to the BHV
material. DBP mitigated structural degradation of BP induced by exposure to oxidizing conditions and
provided resistance to calcification in the rat subdermal implant model. The SOD mimetic approach
demonstrated SOD activity following incorporation into BP as well as after 90 day implantation in either
the rat subdermal implant model or sheep circulatory patch model; thereby supporting the hypothesis that
SOD mimetics may provide sustained protection from oxidants. These studies demonstrate that oxidants
contribute to the structural degeneration of BHV and that an antioxidant material modification may be
used to mitigate this process and to potentially improve the durability of BHV.
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ABSTRACT
OXIDATIVE STRESS AND BIOPROSTHETIC HEART VALVE DEGRADATION: MECHANISMS
AND PREVENTION
Abigail J. Christian
Robert J. Levy, M.D.
Harry Ischiropoulos, Ph.D.

Bioprosthetic heart valves (BHV) are widely used in interventions for symptomatic valvular
disease; however, they begin to fail clinically after 10 years, most frequently due to structural
deterioration.

Calcification has been considered the major mechanism of BHV degeneration

although other mechanisms may be involved. In this work, we investigated the hypothesis that
oxidants contribute to BHV structural degeneration. BHV have been shown to elicit an inflammatory
response from the patient, thereby resulting in the production of reactive oxygen and reactive
nitrogen species which may degrade BHV. To determine the role of oxidants in BHV degeneration,
we analyzed clinically failed BHV explants for markers of oxidation and utilized experimental
systems to identify the consequences of BHV oxidation. Clinical BHV explants were found to have
elevated levels of the tyrosine oxidation product dityrosine, therefore indicating that BHV are
susceptible to oxidation. Exposure of the BHV material glutaraldehyde-fixed bovine pericardium
(BP) to oxidizing conditions demonstrated that oxidation of BHV results in the loss of glutaraldehyde
cross-links, disruption of the collagen structure, and an increase in susceptibility to proteolytic
degradation. To address this mechanism of BHV structural degeneration, we developed two
antioxidant delivery strategies. Our first approach involved covalent immobilization of the oxidant
scavenger 3-(4-hydroxy-3,5-di-tert-butylphenyl) propyl amine (DBP) to BHV leaflet materials
whereas the second method utilized passive incorporation of a catalytic antioxidant, a superoxide
dismutase (SOD) mimetic, into the material. Both strategies demonstrated efficient delivery of an
antioxidant to the BHV material. DBP mitigated structural degradation of BP induced by exposure
to oxidizing conditions and provided resistance to calcification in the rat subdermal implant model.
The SOD mimetic approach demonstrated SOD activity following incorporation into BP as well as
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after 90 day implantation in either the rat subdermal implant model or sheep circulatory patch
model; thereby supporting the hypothesis that SOD mimetics may provide sustained protection
from oxidants. These studies demonstrate that oxidants contribute to the structural degeneration
of BHV and that an antioxidant material modification may be used to mitigate this process and to
potentially improve the durability of BHV.
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Chapter 1: Introduction and Background
1.1 Introduction
Heart valve replacement surgery is the primary treatment option for progressive,
symptomatic heart valve diseases, including aortic valve stenosis and mitral valve prolapse. Each
year more than 300,000 valve replacement surgeries are performed worldwide with both
mechanical and bioprosthetic heart valves (BHV)[1]. BHV are fabricated from glutaraldehyde
treated heterograft tissues and, unlike the alternative mechanical prosthetic valves, have a low risk
of thrombosis [2]. In addition, BHV are the only type of prosthetic valves that can be catheterdeployed, thereby providing a minimal invasive alternative to cardiac surgery [3]. Unfortunately, the
use of BHV is limited by poor durability that contributes to the high device failure rate of 30% after
10 years of implantation [4]. The major cause of BHV failure is structural deterioration associated
with calcification or primary leaflet degeneration [2, 5]. Therefore, there is a significant clinical need
to identify the mechanisms of BHV structural deterioration in order to develop more durable BHV.
1.2 Heart valve disease
The four valves of the human heart regulate blood flow through the heart and to the
peripheral tissues or lungs (Fig. 1.1) [6]. Under normal conditions, blood and pressure build behind
the closed valve which forces the valve open to allow blood flow through the valve [7]. Venous
blood returning to the heart from the peripheral tissues enters the right atrium where it then passes
through the tricuspid valve to the right ventricle. Blood then passes through the pulmonary valve
to reach the lungs via the pulmonary artery. Oxygenated blood enters the left atrium and passes
through the mitral valve into the left ventricle. Blood exits the left side of the heart through the aortic
valve into the aorta, which delivers blood to the peripheral tissues [7]. Under normal conditions,
the atrioventricular valves (mitral and tricuspid) are open during ventricular diastole to allow for
ventricular filling and are closed during ventricular systole to prevent blood flow back into the atria.
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Fig. 1.1 Heart valves and chambers. The valves of the human heart are the mitral, aortic,
pulmonary, and tricuspid. The mitral and tricuspid are the two atrioventricular valves which connect
the atrium and ventricle on the left or right sides of the heart, respectively. The aortic and pulmonary
valves, or semilunar valves, are located in the two arteries that leave the heart, the aorta and
pulmonary artery. Reproduced from [6].
Heart valve disease typically results in either incomplete opening or closing of the valve
which prevents normal blood flow through the valves [4]. The mitral and aortic valves are the most
common sites of valve disease due to their location on the left side of the heart, which pumps blood
to the entire body and therefore generates higher pressure during ventricular or atrial contraction,
as opposed to the right side of the heart which pumps only to the lungs [7]. Valve stenosis, such
as calcific aortic valve disease, is a narrowing of the valve opening due to leaflet thickening and
impaired mechanics, which prevents the valve from fully opening, therefore allowing less blood to
be pumped through the valve with each heartbeat [4, 8]. Valve regurgitation and prolapse describe
conditions of incomplete valve closing, which results in backwards flow of blood [7]. Other causes
of heart valve disease include infective endocarditis, congenital abnormalities such as a bicuspid
aortic valve, and rheumatic disease.
Incomplete valve opening or closing requires the heart to work harder to pump enough
blood through the valve with each beat. To compensate for the required workload, the myocardium
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may dilate and thicken over time [7]. In progressive disease, the myocardium weakens and can
no longer compensate for the valve dysfunction. Without intervention, this leads to congestive
heart failure due to blood and fluid accumulation in tissues, particularly the lungs [7]. The primary
treatment option for symptomatic heart valve disease is valve replacement surgery using prosthetic
heart valves or surgical leaflet repair if possible; there are currently no effective pharmacologic
therapies [4, 7, 9].
1.3 Prosthetic heart valves
The two major classes of prosthetic heart valves are mechanical and bioprosthetic.
Mechanical valves are prepared from synthetic materials such as titanium, metal alloys, or pyrolytic
carbon. The common types of mechanical valves are bileaflet or ball in cage designs (Fig. 1.2) [4].
Although the mechanical valves have good durability with lifespans ranging from 25 to 40 years [4],
they are associated with a high risk of thrombosis due to high shear stress, flow separation, and
red blood cell damage (hemolysis) [10]. Long-term anti-coagulant use is necessary to reduce the
risk of thromboembolism. Despite the disadvantage of anti-coagulation that places the patient at
risk for hemorrhage [10], mechanical valves are still used in approximately 50% of all valve
replacement surgeries [5].

Fig. 1.2. Mechanical valves. (A) Caged ball Starr-Edwards valve (B) Bi-leaflet St. Jude Medical
valve. Adapted from [4].
BHV leaflets are fabricated from glutaraldehyde treated heterograft tissues such as bovine
pericardium (BP), bovine jugular venous valves (BJV), or porcine aortic valve leaflets (PAV). The
glutaraldehyde fixation is necessary to reduce material immunogenicity through antigen masking
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[10]. The heterograft tissues are either mounted on stent struts for catheter-deployed devices or
sewn to a Dacron cushion for implantation [2, 10] (Fig. 1.3). BHV have hemodynamic properties
similar to the native valve and are not associated with a high risk of thrombosis, therefore long-term
anti-coagulation is not required [1, 2, 10]. However, compared to mechanical prosthetic valves,
BHV have a short lifespan with a rate of failure of 30% at 10 years post-implantation and 60% by
15 years post-implantation [4]. This short life span is due to poor durability arising from leaflet
structural degeneration. BHV are widely used despite the short lifespan since they provide an
alternative to the thrombogenic mechanical valves. However, the use of BHV is limited in certain
patient populations such as young children and adolescents, who typically have more rapid BHV
calcification than older human subjects [5, 11, 12].

Fig. 1.3. Bioprosthetic heart valves. (A) Bovine pericardial Carpentier-Edwards bioprosthesis
(B) Porcine aortic valve Medtronic bioprosthesis (C) Transcatheter Edwards Sapien bioprosthesis.
Adapted from [4].
1.4 Structural degeneration of bioprosthetic heart valves
Many factors have been implicated in the structural degeneration of BHV, including
calcification, mechanical stress, and inflammation [2]. Each of these processes involves collagen
disruption, which is important for the structural integrity of BHV leaflets.
BHV calcification is considered the main cause of BHV structural degeneration due to its
prevalence in the majority of explanted clinical BHV [5, 10]. The initiation of BHV calcification
involves the interaction of circulating calcium ions with devitalized cell membranes and intracellular
structures in the heterograft tissue [5]. The initial sites of calcium accumulation grow, ultimately
forming calcium phosphate nodules that cause the BHV leaflets to stiffen, thereby limiting leaflet
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movement [13]. There are many factors that can influence BHV calcification, including normal
regulators of bone formation and calcium metabolism such as osteopontin, osteonectin,
osteocalcin, and alkaline phosphatase [5]. BHV calcification is a significant issue for children and
adolescents who have accelerated calcification as compared to adults [11, 12] which limits the use
of BHV in this patient population.
BHV leaflets are subject to high shear and flexural stresses that have been shown to
potentiate leaflet structural degeneration. These mechanical stresses can disrupt the collagen
structure, which leads to leaflet weakening and in some instances leaflet tears [14]. In addition, it
has been proposed that mechanical stress may also contribute to both calcification and enzymatic
degradation of BHV leaflets through the loss of glycosaminoglycans as well as molecular damage
to collagen [14-16]. Overall, mechanical stress leads to a breakdown of the extracellular matrix
components of the BHV leaflets which leads to material weakening and failure.
The presence of a BHV elicits a host inflammatory response that could lead to BHV
structural degeneration, but this mechanism of degeneration has not been fully elucidated [17-20].
BHV-associated inflammation has been identified through several histology-based studies of
explanted BHV which demonstrated the presence of inflammatory cells such as macrophages and
multi-nucleated foreign body giant cells (Fig. 1.4) [21, 22]. Active inflammatory cells produce
reactive oxygen and nitrogen species (ROS/RNS) as well as matrix metalloproteinases (MMPs)
that degrade extracellular matrix proteins such as collagen [23]; therefore BHV inflammation may
lead to structural degeneration through either proteolytic degradation by MMPs or oxidative stress
from ROS/RNS.
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Fig. 1.4. Inflammatory cell infiltration of BHV. (A) Hematoxlyin and eosin stains of explanted
BHV, arrows indicate cellular filtration (200x) [21] (B) Foreign body giant cell and cellular infiltration
in explanted BHV indicated by arrows (330x) [22].
1.5 Oxidative stress and biomaterial degradation
The term foreign body reaction (FBR) has been used to describe the response to
implantable biomaterials such as pacemaker leads and artificial joints that involves acute and
chronic inflammation as well as fibrous tissue formation [24]. The FBR involves a localized
response to the biomaterial characterized by the migration of activated inflammatory cells to the
surface of the material. The production of ROS/RNS by inflammatory cells is particularly important
in the degradation of synthetic biomaterials including polyurethane and metal alloys since
ROS/RNS reactions with the material leads to damage including surface cracking and pitting,
ultimately resulting in material failure [25-27].
The effects of ROS/RNS on tissue-based biomaterials such as BHV have not been
investigated. However, studies with purified collagen, the major component of the heterograft
tissues used in the fabrication of BHV, have shown that ROS/RNS reactions result in oxidation of
cross-linked molecules, collagen fibril fragmentation, and increased susceptibility to proteolytic
enzymes such as MMPs [28-31]. Oxidants have been shown to disrupt both the secondary and
tertiary structure of collagen through cleavage of intramolecular cross-links [31]. This disruption of
the collagen structure may be responsible for the increased susceptibility to proteolysis following
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exposure to oxidants. In addition, collagen oxidation results in fibril fragmentation that may allow
proteases to more easily access and degrade collagen [32]. Therefore, based on these effects of
collagen oxidation, oxidation of a collagen-based biomaterial may contribute to BHV structural
degradation.
The major focus for improving BHV durability has been the prevention of BHV calcification
through the use of material pre-treatments or modifications. However, BHV degeneration remains
a significant clinical issue and may be addressed by shifting the focus from calcification to
alternative mechanisms of BHV structural deterioration. We hypothesize that oxidants contribute
to BHV degeneration. This hypothesis is supported by evidence of BHV-related inflammation as
well as the known structural and functional effects of oxidation of collagen. Furthermore, mitigation
of BHV oxidative damage with compounds that scavenge oxidants could improve BHV durability.
1.6 Antioxidant modifications of biomaterials
Incorporation or modification of materials with antioxidants has been studied as an
approach to prevent oxidative damage of synthetic materials used in medical applications [27, 33,
34]. Compounds such as α-tocopherol have demonstrated efficacy in preventing oxidative damage
of polymers such as poly(etherurethane urea) that may be used in medical implants [35]. There
are several strategies that have been employed for the modification of polymeric materials with
antioxidants including incorporation prior to polymerization or surface modification [34, 36]. These
proof-of-principle studies demonstrated that incorporation of an antioxidant in a biomaterial
successfully prevents oxidative damage and thereby may be a useful strategy to improve the
durability of clinically-used biomaterials.
Previously, antioxidant incorporation or modification to BHV has not been developed as an
approach to improving BHV durability. However, attachment of a compound, such as an anticalcification agent [37], has been done using covalent methods. These studies utilized either the
residual aldehyde groups introduced with glutaraldehyde or carbodiimide-activated carboxyl groups
to react and bind an amine-containing compound through the formation of either Schiff bases or
amide bonds, respectively [37-39]. In addition to covalent modification, it may be possible to
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passively incorporate, or without a chemically-driven reaction, a hydrophobic or ionic compound
into BHV materials. Both methods will be discussed as potential strategies for modification of BHV
with an antioxidant.
In order to covalently immobilize a compound to a material, the material must either contain
reactive functional groups such as terminal amines or those groups must be introduced. Collagen
contains lysine and asparagine residues containing terminal amines, which are utilized in
glutaraldehyde fixation for BHV, as well as glutamate and aspartate with terminal carboxyl groups
[40-43]. These carboxyl groups are not currently utilized in the preparation of BHV leaflet materials
and therefore may be employed for antioxidant incorporation. The antioxidants previously used in
studies with synthetic materials are not ideal for conjugation to carboxyl groups due to the lack of
accessible functional groups necessary for reaction with the material.

A commonly used

conjugation reaction involving carboxyl groups is carbodiimide-driven activation of carboxyl groups
and subsequent reaction with reactive amines [44]. This type of carbodiimide-driven chemistry has
been studied as an alternative cross-linking strategy for BHV materials and therefore may be
effective for the immobilization of a compound to the material [39, 45]. The combination of a
carbodiimide-driven reaction and an antioxidant with a reactive amine may be used to modify BHV
materials.
The alternative method, passive incorporation, relies on the structure of the compound that
is to be incorporated. Lipophilic rather than hydrophilic compounds have more efficient uptake into
tissues, such as those used in the fabrication of BHV, since these compounds are able to partition
in lipid membranes and can interact with extracellular matrix proteins such as collagen through
hydrogen bonding [46]. In addition, a charged compound can interact with charged regions of the
tissue, which would include negatively or positively charged amino acid residues of collagen, to
provide additional electrostatic interactions that could stabilize the compound within the tissue [47].
Depending on the characteristics of the compound for passive incorporation, both methods for
modifying BHV could provide sustained, local delivery of an antioxidant.
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1.7 Approach 1: covalent immobilization of DBP
The first proposed strategy for mitigating BHV oxidative degradation involves the
immobilization of an oxidant scavenging compound to the BHV material prior to clinical use. To
accomplish this, we proposed the use of an analogue of butylated hydroxytoluene (BHT) and a
carbodiimide-driven modification scheme.
BHT is a phenolic compound commonly used as a food additive due to its ability to react
with oxidants such as hydroxyl and peroxyl radicals to terminate potentially damaging reactions
including lipid peroxidation [48, 49] (Fig. 1.5A). BHT undergoes one electron oxidation to form a
phenoxyl radical which can subsequently scavenge an additional radical [48, 50]. BHT is not an
ideal candidate for covalent immobilization to a BHV material since it does not contain a reactive
functional group that could be utilized in a conjugation reaction. However, an analogue of BHT
with the appropriate reactive group could be a candidate for immobilization to BHV.
Previously, BHT or di-tert-butyl phenol derivatives synthesized in the Levy lab were
attached to polyurethane through bromoalkylation or bulk modification [27, 36, 51]. The same
attachment scheme cannot be used BHV materials since BP does not have the appropriate surface
chemistry [40, 52]. However, di-tert-butyl phenol with an added terminal amine could react with
carbodiimide-activated carboxyl groups in BHV materials to form an amide bond. The proposed
compound, 3-(4-hydroxy-3,5-di-tert-butylphenyl) propyl amine (DBP), has the BHT parent
compound for antioxidant activity and an amine with an alkyl linker for reactivity with BHV materials
(Fig. 1.5B).

Fig. 1.5 Structures of BHT and DBP. (A) Butylated hydroxytoluene (BHT) or 2,6-di-tert-butyl-4methylphenol and (B) 3-(4-hydroxy-3,5,-di-tert-butylphenyl)propyl amine (DBP).
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Carbodiimides are frequently used in amine-carboxyl conjugation reactions [44, 53]. In the
presence of N-hydroxysuccinimide (SuOH), carbodiimide activation of carboxyls results in the
formation of stable N-succinimidyl ester intermediates which are then able to react with an amine
to form an amide bond. The proposed reaction to attach DBP to BHV materials is shown below
(Fig. 1.6).
C(CH3)3
OH
OH
(H3C)3C

COOH

Collagen fiber

EDC, SuOH
50% EtOH
pH ca. 5.5

COOSu

Collagen fiber

C(CH3)3

O

C(CH3)3

NH

H2 N
Collagen fiber

Fig. 1.6 DBP modification scheme.
Carboxyl groups are activated with 1-ethyl-3-(3dimethylaminopropyl)-carbodiimide (EDC) in the presence of SuOH to form stable N-succinimidyl
ester intermediates that can then react with DBP. Scheme prepared by Ivan Alferiev.
We propose that immobilized DBP will remove oxidants that could otherwise damage the
BHV material. Due to the covalent interaction between DBP and carboxyl groups of collagen in
BHV heterograft materials, DBP is expected to be stably bound to the BHV material.
1.8 Approach 2: non-covalent incorporation of a superoxide dismutase (SOD) mimetic
The SOD enzymes control intracellular and extracellular superoxide levels. The three SOD
enzymes are cytosolic Cu/Zn SOD (SOD1), mitochondrial MnSOD (SOD2), and extracellular Cu/Zn
SOD (SOD3) [54]; the enzymes differ in terms of subcellular localization and reactive metal. These
enzymes catalyze the dismutation of superoxide to hydrogen peroxide and molecular oxygen
through cycling of the oxidation state of the metal center of the enzyme, which is represented by
the following reactions: Mn+1-SOD+ O2-•  Mn-SOD + O2 and Mn-SOD + 2H+ + O2-•  Mn+1-SOD +
H2O2. In addition, SOD3 has been shown to prevent oxidative fragmentation of type I collagen [55].
Superoxide can cause damage to collagen [56], but compared to other oxidants, superoxide is a
weak oxidant. However, superoxide is involved in the production of stronger oxidants including
hydroxyl radicals and peroxynitrite through metal-catalyzed reactions with hydrogen peroxide or
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nitric oxide, respectively [57, 58]. Therefore superoxide dismutation by SOD may prevent oxidative
damage through both the removal of superoxide and the decreased production of hydroxyl radicals
and peroxynitrite.
The pharmacological use of native SOD enzymes is limited by both the size of the enzyme,
which prevents it from crossing cell membranes, as well as its short circulating half-life since it is
susceptible to degradation by proteases [54]. Due to these limitations, synthetic compounds, or
SOD mimetics, have been developed for potential clinical use. The conserved structural features
of the currently available SOD mimetics are a redox active metal center and a protective ring
structure that prevents the dissociation of the metal ion and provides electrostatic guidance for
superoxide to the reactive metal center [54, 59]. The primary design concern for the development
of SOD mimetics is the reduction potential of the metal center (E1/2), which indicates the ability of
the metal to accept and donate electrons in order to dismutate superoxide [60, 61]. Native SOD
enzymes have an E1/2 value of +300 mV versus the normal hydrogen electrode (NHE) and are able
to equally accept and donate electrons to superoxide [61] thereby not limiting either the reduction
or oxidation involved in superoxide dismutation.

The SOD mimetics vary in their reduction

potentials, with the most potent falling in a range of +220-350 mV [62].
Manganese pyridyl porphyrin (MnPyP) SOD mimetics have been optimized for their
electrostatic properties, bioavailability, and low toxicity by the Batinic-Haberle group from Duke
University. These compounds are the most potent SOD mimetics based on both the reduction
potential of the manganese center as well as the kcat values for SOD dismutation [62, 63]. These
compounds catalyze the dismutation of superoxide through the cycling of the oxidation state of
manganese, similar to the native SOD enzymes: Mn(III)P+5 + O2-•  Mn(II)P+4 + O2 and Mn(II)P+4
+ 2H+ + O2-•  Mn(III)P+5 + H2O2 [64]. Three SOD mimetics were provided by the Batinic-Haberle
group for use in mitigating oxidative degradation of BHV (Fig. 1.7).
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Fig. 1.7 Structures of Mn porphyrin SOD mimetics. (A) Mn(III) meso-tetrakis(N-ethylpyridinum2-yl)porphyrin (MnTE-2-PyP), (B) Mn(III) meso-tetrakis(N-octylpyridinum-2-yl)porphyrin (MnTnOct2-PyP), (C) Mn(III) meso-tetrakis(N-octylpyridinum-3-yl)porphyrin (MnTnOct-3-PyP).
In addition to the potent SOD activity of MnPyP, these compounds are good candidates for
passive incorporation in BHV materials due to both the charge of the compounds as well as the
alkyl side chains that could interact with the tissue through hydrogen bonding. Based on these
properties, it may be possible to passively incorporate these compounds in BHV materials such as
BP to provide stable, local antioxidant activity. Unlike DBP, an SOD mimetic catalytically removes
superoxide thereby theoretically not expending its redox capacity.
1.9 Experimental systems of biomaterial oxidative damage
In order to study biomaterial oxidative stress, experimental systems that accelerate this
process have been developed. Typically these systems involve exposure to hydrogen peroxide
and redox-capable metal ions such as cobalt (II) or iron (II) to produce hydroxyl radicals through
the Fenton reaction (Fe2+ + H2O2 +H+ → Fe3+ + HO• + H2O) [65-67]. However, these in vitro systems
are used in non-physiological levels to induce oxidative damage comparable to long-term in vivo
injury [33].

Tissue-based biomaterials have not previously been tested in these accelerated

systems. Therefore, it may be necessary to adjust the oxidizing conditions in order to better
recapitulate the processes that occur in vivo. Although these systems do use non-physiologic
conditions, they provide a means for characterization of material oxidative damage and evaluation
of potential antioxidant material modifications.
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1.10 Animal models
The primary animal model used to assess BHV degradation is the rat subdermal implant
model. This model uses juvenile rats to achieve accelerated calcification of the BHV material
implants. Compared to adult or mature rats, juvenile rats have higher serum levels of calcium,
phosphorus, osteocalcin, and active alkaline phosphatase [68], which contribute to the acceleration
of implant calcification. It has not been determined whether the location of the implant (subdermal
rather than exposed to circulation) also contributes to accelerated calcification in this model. This
model has been widely used in studies involving BHV calcification but few studies have assessed
other mechanisms of BHV degradation in this system. Degeneration associated with mechanical
forces, both shear and flexural, cannot be studied in this system since the implants are static.
Additional characterization of this model will be necessary to determine whether oxidative stress
related BHV degradation can be assessed.
The major preclinical large animal models for testing BHV are porcine or ovine valve
replacement since these systems provide both exposure to circulation and shear forces in the
correct anatomical location [69, 70]. However, these models have several challenges including
expense, requirement for surgically trained technicians and physicians, as well as a clinical grade
BHV that can be sewn in the valve position. The preparation of the clinical grade BHV is of
particular concern since this typically requires a partnership with a BHV manufacturer in order to
provide high quality BHV leaflets mounted to either a stent or Dacron sewing ring. An alternative
ovine model has been developed in order to avoid both the valve replacement surgery and need
for a clinical-grade BHV while still providing exposure to circulation and mechanical forces. This
model involves the implantation of BHV leaflet patches in the aorta, pulmonary artery, and left
atrium [71]. Since this is still an ovine model, there are significant costs associated with animal
care as well as the surgical procedures, but it does have reduced costs as compared to the
alternative of mitral valve replacement.
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1.11 Aims of dissertation
The major aims of my dissertation were to determine whether oxidative stress contributes
to BHV degeneration and to develop pharmacological interventions that could mitigate this process.
The first aim was to determine whether BHV are susceptible to oxidative stress and
determine how this could lead to structural deterioration. Clinical BHV explants were analyzed for
markers of oxidative stress to demonstrate that BHV are susceptible to oxidation. In order to
determine the functional consequences of BHV oxidation, the BHV material BP was subject to the
accelerated oxidative damage system as well as rat subdermal implantation. The endpoints
assessed in studies with BP included both material and mechanical effects that could result in
device failure. Together these approaches identified oxidative stress as a mechanism of BHV
structural degeneration.
The second aim of my dissertation was to develop a pharmacological strategy to mitigate
oxidation-mediated BHV structural degeneration, which was characterized in the first aim, and
determine whether such an approach would effectively interfere with this process of BHV
degradation.

BP was modified through covalent immobilization of the oxidant scavenging

compound DBP. Modified BP was subject to the accelerated oxidative damage model as well as
the rat subdermal implant model in order to demonstrate that the DBP modification attenuated BHV
oxidation.
In the final aim, a non-covalent modification of BP with an SOD mimetic was developed in
order to improve upon the first modification strategy. SOD mimetics have the advantage over
stoichiometric antioxidants such as DBP in that they can be regenerated by cellular reductants,
thereby prolonging the antioxidant activity. In addition to comparing the type of compound used in
the modification, the process of antioxidant incorporation could be optimized by determining
whether covalent or non-covalent immobilization is more effective in sustained local delivery to
BHV. The SOD mimetic loaded BP samples were tested in both the rat subdermal implant system
and the sheep patch model in order to broadly assess the degeneration of BHV in terms of oxidation
as well as calcification.
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Chapter 2: The susceptibility of BHV leaflets to oxidation
This chapter has been published:
Christian AJ, Lin H, Connolly JM, Alferiev IS, Ferrari G, Hazen SL, Ischiropoulos H, Levy RJ. The
susceptibility of bioprosthetic heart valve leaflets to oxidation. Biomaterials. 2014; 35:2097-102.
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2.1 Abstract
Structural degeneration BHV leaflets is a significant clinical issue that results in early device
failure. Here we investigated the hypothesis that BHV are susceptible to oxidative stress and that
this process results in leaflet degeneration. Explants of failed clinical BHV explants were analyzed
for markers of oxidative stress including several tyrosine oxidation products. Dityrosine, a crosslink
that is an oxidation product of tyrosine, was elevated in the BHV explants, and was undetectable
in non-implanted BHV materials glutaraldehyde treated bovine pericardium (BP) and porcine aortic
valve leaflets (PAV). This elevation of dityrosine indicates that BHV are susceptible to oxidative
stress. To identify a mechanism of oxidation-mediated structural degeneration, BP was exposed
to experimental oxidizing conditions (FeSO 4/H2O2), which resulted in significant collagen
deterioration, loss of glutaraldehyde cross-links, and increased susceptibility to collagenase
degradation; thereby demonstrating that oxidation of BHV causes material degeneration. In the rat
subdermal implant model of BHV calcification, BHV displayed only modest oxidation despite the
presence of inflammation. However, in short-term sheep pulmonary artery catheter-deployed BHV
explants, the elevation of dityrosine correlated with the clinical explants, which suggests that direct
exposure to blood flow may be necessary for BHV oxidation. The formation of dityrosine in BHV
explants and the effects of exposure to oxidizing conditions on the integrity of the collagen structure
and glutaraldehyde cross-links support the hypothesis that oxidative stress is a mechanism of BHV
structural degeneration.
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2.2 Introduction
BHV are widely used in heart valve replacement surgeries for their hemodynamic
properties and low risk of thromboembolism in comparison with mechanical heart valves [2].
Unfortunately, BHV have poor durability caused by leaflet structural deterioration associated with
calcification, mechanical stress, or inflammation [5, 14, 18, 21].

Due to the prevalence of

calcification in failed clinical BHV explants, calcification prevention and mechanisms have been the
major focus of BHV research [5].

Despite advancements in these areas, particularly the

development of BHV anti-calcification strategies, structural degeneration of BHV leaflets remains
a significant clinical issue.

Therefore, in this work we focused on the role of a non-calcific

mechanism, oxidative stress, in BHV structural deterioration.
Oxidative stress is a significant mechanism of material degradation for synthetic
biomaterials such as polyurethane since reactions of ROS/RNS with the material leads to surface
pitting and cracking [25, 36]. The effects of ROS/RNS on a tissue-derived biomaterial such as BHV
have not previously been investigated. However, previous studies have demonstrated that BHV
elicit a host inflammatory response, thereby locally producing ROS/RNS [21, 22, 72]. In addition,
collagen, the primary component of BHV materials, is susceptible to fragmentation and cross-link
breakdown as a result of oxidation; this also leads to an increase in susceptibility to proteolytic
degradation [28, 29, 56, 73, 74]. Based on this evidence, we hypothesized that oxidative stress
resulting from the production of ROS/RNS by inflammatory cells is involved in BHV structural
degeneration. In order to verify this hypothesis, we first analyzed clinical BHV explants for markers
of oxidative stress to demonstrate that BHV oxidation occurs in patients.
There are several types of markers that have been used to identify oxidative stress in
biological samples, which include lipid [75], DNA [76], and protein [77, 78] oxidation products. BHV
leaflets are composed primarily of protein (collagen) rather than DNA and lipids since these
components are removed by either glutaraldehyde cross-linking or ethanol pre-treatment, which is
used in a subset of clinical valves [79]. Therefore, protein oxidation products may be more useful
for identifying oxidative stress in BHV leaflets. Modifications of proteins by oxidants have been
widely studied as potential biomarkers for various disease states associated with oxidative stress
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[78, 80-83]. Phenylalanine and tyrosine are common sites of oxidant attack and result in the
formation of o,o-dityrosine, ortho-tyrosine, meta-tyrosine, nitrotyrosine, chlorotyrosine, and
bromotyrosine; the adduct formed is dependent on the type of oxidant involved [77, 78, 84]. For
example, bromotyrosine and chlorotyrosine are formed through reactions involving brominating and
chlorinating species such as hypobromous acid and hypochlorous acid, respectively [85]. Higher
levels of product oxidation products are expected in tissues subject to oxidative stress, potentially
such as BHV materials.

The mentioned phenylalanine and tyrosine oxidation products were

therefore assessed in clinical BHV explants.
Due to the significance of oxidative damage to synthetic biomaterials, experimental
systems of accelerated oxidative damage have been developed to study these processes [65-67].
BHV materials such as BP and PAV have not previously been tested in such a system. However,
these accelerated systems may be useful in the identification of functional consequences of
oxidative stress which would otherwise be difficult to study in short-term animal models. Since
oxidation is known to cause collagen fragmentation, cross-link breakdown, and an increase in
susceptibility to proteolytic degradation, these effects were assessed in BHV materials using an
accelerated oxidative degradation model.
The rat subdermal implant model is commonly used to assess BHV degradation associated
with calcification since this system results in accelerated implant calcification due to the use of
juvenile rats that have higher serum concentrations of pro-calcification factors such as alkaline
phosphatase [43, 68]. BHV oxidation was assessed in this model to determine whether this system
could be useful in studying non-calcific mechanisms of BHV structural degeneration. In addition to
inflammation, which can be studied in the subdermal implant model, other factors such as direct
circulatory contact and exposure to mechanical forces are likely involved in the progression of BHV
oxidation and are not represented in this system [86, 87]. Therefore, it may be necessary to use
alternative animal models to fully recapitulated non-calcific mechanisms such as oxidative stress.
In addition to clinical BHV explants and rat subdermal explants, catheter-deployed BHV
explants from a sheep circulatory model were analyzed for BHV oxidation to determine whether
circulatory exposure is necessary for BHV oxidation. The availability of these explants provided
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valuable comparison between animal models used in the assessment of BHV as well as with clinical
BHV explants.
Here we used several approaches to assess the susceptibility of BHV leaflets to oxidation
and the functional consequences of this process. These approaches included analysis of clinical
and sheep BHV explants for protein oxidation products, BHV degradation in an accelerated
oxidative damage model, and rat subdermal implantation of the BHV material BP for assessment
of oxidation endpoints.
2.3 Materials and Methods
Materials
Glutaraldehyde and a Von Kossa staining kit were purchased from Polysciences, Inc
(Warrington, PA). Biosol and Bioscint were purchased from National Diagnostics (Atlanta, GA). 3Hglutaraldehyde was purchased from American Radiolabeled Chemicals (St. Louis, MO). All
chemicals unless otherwise specified were purchased from Sigma Aldrich (St. Louis, MO).
Human BHV explants
Between 2010 and 2012, 3 PAV BHV and 16 BP BHV were collected from patients
according to the University of Pennsylvania IRB approved protocol #809349. Informed consent was
obtained from patients requiring repeat aortic valve replacement due to a failing BHV at the Hospital
of the University of Pennsylvania. Patients with bioprosthetic aortic valve failure due to pannus,
thrombus, and endocarditis were excluded from the study. Explanted bioprosthetic aortic valves
were fixed in 10% buffered formalin overnight, followed by dehydration in 70% ethanol solution,
and stored at 4˚C. A single leaflet from each clinical BHV explant was embedded in paraffin
according to standard procedures for histology and quantification of oxidized amino acids.
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Calcification
For quantification of calcium content in clinical BHV, a single leaflet was hydrolyzed in 6 N
HCl at 100 °C and dried under air flow. The hydrolysates were reconstituted in 0.01 N HCl. Calcium
quantification was done using a Perkin Elmer 2380 atomic absorption spectrophotometer [88]. The
Von Kossa staining method was used for qualitative calcification determination [89]. Paraffin
sections of explanted BHV were rehydrated with ethanol and stained with silver nitrate using a Von
Kossa Calcium Kit according to manufacturer directions.
Morphology
Masson’s trichrome and picrosirius red stains were used to assess explant morphology.
Paraffin sections (6 µM) were prepared for staining procedures. Slides were rehydrated through
xylene and ethanol. For Masson’s trichrome, slides were stained according to the kit protocol
(Sigma). For picrosirius red, slides were stained for 1 hour with 0.1% Sirius red in saturated picric
acid [90]. Stained sections were then dehydrated and mounted with permount for microscopy.
Quantification of oxidized amino acids
Oxidized amino acid quantification was performed by the lab of Stanley Hazen at the
Cleveland Clinic. Oxidized amino acids were quantified by established stable isotope dilution liquid
chromatography tandem mass spectrometry (LC MS/MS) methods on an AB SCIEX API 5000 triple
quadrupole mass spectrometer interfaced with an Aria LX Series HPLC multiplexing system
(Cohesive Technologies Inc., Franklin, MA) [85]. Briefly, paraffin embedded BHV leaflets were
deparaffinized by xylene. [13C6]-labeled oxidized amino acid standards and universal labeled
precursor amino acids ([13C9,15N1]tyrosine and [13C9,15N1]phenylalanine) were added to samples
after protein delipidation and desalting with a single phase mixture of H2O/methanol/H2O-saturated
diethyl ether (1:3:8 v/v/v). Proteins were hydrolyzed under argon gas in methane sulfonic acid, and
then samples were passed through C18 solid-phase extraction column (Discovery – DSC18
minicolumn, 3 ml, Supelco, Bellefone, PA) prior to MS analysis. Individual oxidized amino acids
and their precursors were monitored by characteristic parent to product ion transitions unique for
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each isotopologue monitored. Results are expressed relative to the content of the precursor amino
acids, tyrosine and phenylalanine.
BP preparation
Fresh BP obtained from an abattoir was treated with 0.625% glutaraldehyde or 0.625% 3Hglutaraldehyde (specific activity 24 µCi/mmol) in HEPES buffer pH 7.4 for 7 days at room
temperature with gentle shaking. All BP samples were stored in 0.2% glutaraldehyde [68].
Accelerated oxidative damage model
A modified model of accelerated oxidative damage previously used with polymeric
biomaterials was used to assess BP oxidation [66]. BP samples were incubated in PBS or 1%
H2O2/100 µM FeSO4 for 7 days with solution changes every 2-3 days. Lyophilized samples were
weighed at the start and end of treatments to determine bulk material loss. Picrosirius red staining
was done on formalin-fixed, paraffin-embedded samples. BP treated with 3H-glutaraldehyde was
monitored for the release of 3H into the reaction solutions, as well as in the solubilized tissues at
the end of the treatments.

3H-BP

were solubilized with Biosol and analyzed by liquid scintillation

counting in Bioscint following exposure to oxidizing conditions.

Collagenase digestion was

performed on lyophilized BP following the 7 day oxidation assay. Collagenase (600 U/mL) was
added to BP samples and incubated for 24 hours at 37°C. Digestion by collagenase was measured
as a loss of weight following collagenase treatment.
Rat subcutaneous BP implants
Three week old male, Sprague-Dawley rats (60-90 grams) were used for subdermal
implantation studies [68]. Surgical procedures were performed according to guidelines from the
Institutional Animal Use and Care Committee at the Children’s Hospital of Philadelphia. Rats were
anesthetized with isofluorane and shaved prior to preparing two dorsal subdermal pouches. BP
samples were implanted in subdermal pouches for 2-3 samples per animal. The BP samples were
explanted with (en bloc) or without surrounding tissue intact at 7, 21, or 90 days. For “pre-oxidized”
studies, BP was exposed to 1% H2O2/100 µM FeSO4 prior to implantation. In order to assess the
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inflammatory response to the BP implant, the implants were removed en bloc, with the surrounding
tissue intact. Formalin-fixed en bloc sections were embedded in paraffin and stained with Masson’s
Trichrome, hematoxylin and eosin (H&E), or myeloperoxidase (MPO) immunohistochemistry. MPO
immunohistochemistry was performed by the CHOP Pathology core facility. Image analysis of H&E
and Masson’s Trichrome stains was used to determine the thickness of the cellular and fibrous
capsules, respectively. For image analysis 5-10 images were taken of each biologic replicate (n=35 per group) and 5 measurements were made per image to account for heterogeneity in the
inflammatory or fibrous capsules. For cellular infiltration localization studies, en bloc explants were
oriented in the plane of the tissue rather than in a cross-sectional area. Three 8 µm serial sections
were made at each depth with 100 µm separating each depth. Image analysis was performed with
ImageJ to determine the percent of hematoxylin stained cells in each section. For each biologic
replicate, 3-5 images were used with 5 measurements per image to determine percent hematoxylin
staining of total area.
Hydroxyproline quantification
Hydroxyproline content of rat subdermal explants was quantified with 1H-NMR, performed
at 400MHz on a Bruker Avance III™ 400 wide-bore spectrometer by Suzanne Werhli of the CHOP
NMR core. Explant acid hydrolysates (0.6 mL) were introduced in a 5 mm NMR tube. An external
standard made of a sealed capillary containing a solution of trimethylsilylpropionic acid (TSP) in
D2O was used as chemical shift reference and quantification standard. Fully relaxed proton spectra
were acquired with a 5 mm BBO probe. Standard acquisition conditions were as follows: PW 45o,
TR 8s, water saturation during the relaxation delay, SW 6775 Hz, TD 64k and 64 scans. Explant
acid hydrolysates, hydroxyproline, or acid hydrolysates with added hydroxyproline were first
analyzed to identify spectral peaks unique to hydroxyproline. Quantification of the hydroxproline
peaks was performed by normalization to the TSP standard (Fig. 2.1), provided by Suzanne Werhli.

22

Fig. 2.1 Hydroxyproline quantification by 1H-NMR. Spectral peaks corresponding to
hydroxyproline in tissue acid hydrolysates (A). Normalization of peaks to the internal standard TSP
(B).
Differential scanning calorimetry
Cross-linking of non-implanted glutaraldehyde fixed BP and rat subdermal BP explants
was measured by differential scanning calorimetry (DSC) on a Perkin Elmer DSC 7 [91]. Samples
that were hermetically sealed in aluminum pans were placed in the DSC where sample temperature
was ramped from 25°C to 100° C until the endothermic peak corresponding to thermal denaturation
was observed.
Sheep bovine jugular vein BHV pulmonary artery implants
Percutaneous bilateral branch pulmonary artery valve implantation of BJV BHV was
performed in an ovine model of postoperative pulmonary valve insufficiency as previously
described by the Gorman Cardiovascular Research Group [92]. BJV were explanted at 3 months
Statistical Methods
Results are shown as the mean ± standard error for the mean. Single ANOVA with Tukey’s
test, Mann-Whitney rank sum test or a two tailed t-test were used to determine significance, which
was defined as a p value less than 0.05.
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2.4 Results
Characterization of clinical BHV
The clinical BHV explants were characterized in terms of patient demographics,
calcification, and morphology. Of the 19 clinical BHV, 16 were BP and 3 were PAV. The patient
population from which the clinical BHV explants were obtained had roughly equal numbers of males
and females and concomitant heart surgery was performed in 8 of the subjects (Table 2.1). The
explanted BP BHV were primarily Carpentier Edwards except for one Sorin BHV. The majority of
the patients had underlying medical conditions (Table 2.1). No correlations were made from patient
data with BHV degeneration processes due to the small sample size.
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Table 2.1 Clinical patient characteristics of BHV explants. NYHA, New York Heart Association;
CABG, Coronary artery bypass grafting.
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Calcification of the clinical BHV explants was assessed using both quantitative and
qualitative methods. Variable amounts of calcification were present in both PAV (Fig. 2.2A) and
BP (Fig. 2.2B) BHV explants as assessed by Von Kossa, which was scored on a scale of 0 (no
calcium staining) to 3 (most severe) to demonstrate the distribution of explant calcification (Fig.
2.2C). By atomic absorption spectroscopy, the mean calcium level in explanted BHV was 106.2
µg calcium/mg tissue ± 23.9. These results demonstrate variable degrees of clinical BHV explants
calcification, but with a mean corresponding to previously reported values [93].
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Fig. 2.2 Calcification of clinical BHV. Von Kossa staining of (A) PAV and (B) BP BHV explants,
40x. (C) Histogram showing distribution of calcium scores from Von Kossa staining.
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Morphology of both the PAV and BP BHV was assessed by picrosirius red and Masson’s
trichrome stains to identify structural deterioration. Picrosirius red and Masson’s Trichrome both
stain collagen, but only Masson’s Trichrome differentiates cells, smooth muscle, and collagen [94].
PAV, both non-implanted and explanted BHV, stain mostly for collagen (blue with Masson’s
Trichrome, red with picrosirius red) with some cellular staining (Fig. 2.3). BP is also primarily
collagen but is more organized than PAV with parallel collagen fibrils (Fig 2.4). BHV explants, both
PAV and BP, did not demonstrate collagen deterioration as would be expected with clinical use.
These results show that despite clinical failure, the BHV explants do not have significant structural
deterioration.

Fig. 2.3 Morphology of clinical PAV BHV. Masson’s trichrome of PAV, (A) non-implanted and
(B) explants Picrosirius red of PAV, (C) non-implanted and (D) explants, 200x.
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Fig. 2.4 Morphology of clinical BP BHV. Masson’s trichrome (A) non-implanted and (B) explanted
BP. Picrosirius red (C) non-implanted and (D) explanted BP, 200x.
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Oxidized amino acids in clinical BHV
Six structurally distinct oxidized amino acids were quantified in clinical PAV and BP BHV
explants to determine whether these materials are susceptible to oxidative stress and to assess
whether specific oxidants or pathways are involved in BHV oxidation. PAV and BP clinical BHV
were analyzed separately to determine whether oxidation was dependent on the type of heterograft
material. The clinical PAV BHV explants had decreased levels of meta-tyrosine (p<0.001), orthotyrosine (p<0.001), and chlorotyrosine (p=0.024) as compared to non-implanted PAV (Fig. 2.5).
Dityrosine was not present in non-implanted PAV but was measured in the PAV BHV explants
(p=0.198). Nitrotyrosine and bromotyrosine levels were not significantly different between nonimplanted PAV and PAV BHV explants. The presence of all oxidation products except dityrosine
in the non-implanted control material indicates that some oxidation may occur in either the animal
from which the tissue is derived or in the processing and handling of the tissues for BHV fabrication.
Therefore, these markers may not represent an oxidative environment resulting from the patient’s
inflammatory response to the BHV. However, the accumulation of dityrosine in PAV BHV explants
and absence in control material indicates that dityrosine may be a marker of oxidative stress for
BHV explants.
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Fig. 2.5 Oxidized amino acids in clinical PAV BHV. Meta-tyrosine (A), ortho-tyrosine, (B),
nitrotyrosine (C), dityrosine (D), chlorotyrosine (E), and bromotyrosine (F), n=3. * p<0.05 explants
vs. non-implanted control.
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The same structurally distinct oxidation products analyzed in PAV BHV explants were
quantified in BP BHV explants. Compared to non-implanted BP, clinical BP BHV explants had
elevated levels of meta-tyrosine (p< 0.01), ortho-tyrosine (p< 0.01), and dityrosine (p< 0.01);
nitrotyrosine levels were lower in explants (p=0.0156) (Fig. 2.6).

There were no significant

differences in bromotyrosine or chlorotyrosine between non-implanted BP and BP BHV explants.
These results are similar to the PAV BHV results in that all oxidation products except for dityrosine
are present in non-implanted materials. Together the PAV and BP BHV results demonstrate that
dityrosine may be a marker specific to BHV oxidation since it is not present in non-implanted
materials and is independent of material type (PAV or BP).
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Fig. 2.6 Oxidized amino acids in clinical BP BHV. Meta-tyrosine (A), ortho-tyrosine, (B),
nitrotyrosine (C), dityrosine (D), chlorotyrosine (E), and bromotyrosine (F), n=16. * p<0.05
explants vs. non-implanted control.
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Experimental oxidation of BHV material BP
Analysis of the clinical BHV explants demonstrated BHV susceptibility to oxidation,
however, no direct functional effects of oxidation were identified. Therefore, BP was subject to a
model of accelerated oxidative damage (1% H2O2, 100 µM FeSO4) to assess structural effects of
BHV oxidation that may result in material failure. Oxidation of BP in this system resulted in
significant destruction of the collagen structure as shown by picrosirius red staining of collagen
(Fig. 2.7A-B). In addition, oxidation caused significant mass loss of BP as well as increased
digestion by collagenase (Fig. 2.7C). BP that had been cross-linked with 3H-glutaraldehyde was
tested in this system to determine whether oxidizing conditions causes a loss of the glutaraldehyde
cross-links. In PBS incubations over 7 days, the amount of 3H-glutaraldehyde released was 14.1 ±
1.3% of the total 3H-glutaraldehyde incorporated in the tissue, whereas with oxidation the loss was
75.7 ± 5.4% (Fig. 2.7D). These results indicate that oxidation of BP results in significant material
degeneration including mass loss, collagenase digestion, and breakdown of glutaraldehyde crosslinks.
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Fig. 2.7 Experimental oxidation of BP. BP exposed to 1% H2O2 and 100 uM FeSO4 for 7 days.
Picrosirius red staining, untreated BP (A) and oxidized BP (B), 200x. Material weight loss with
oxidation and collagenase digestion (C). Release of 3H-glutaraldehyde from BP with and without
oxidation (D). p<0.05 oxidized BP vs untreated BP.
Oxidation of BP rat subdermal explants
To determine if oxidation of the BHV material BP occurs in the rat subdermal implant model
of BHV calcification and whether this model could be useful in further studies of BHV oxidation, BP
explants were assessed for endpoints that may reflect BHV oxidative damage including loss of
hydroxyproline, collagenase digestion, shrink temperature, and collagen deterioration. Since BHV
oxidation had not previously been assessed, several endpoints were used in order to identify
parameters of oxidative damage.
Hydroxyproline is an amino acid abundantly found in collagen, the primary protein
component of BHV materials such as BP [95]. A loss of hydroxyproline content would therefore
correlate with a decrease in collagen content. Hydroxyproline was quantified by 1H-NMR in acid
hydrolysates of non-implanted BP as well as rat subdermal explants from 21 and 90 day studies.
Hydroxyproline content was significantly lower in the explanted materials as compared to nonimplanted BP (Fig. 2.8A). Additionally, hydroxyproline content was lowest in 90 day explants
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indicating a progressive loss of hydroxyproline or collagen throughout the duration of implantation.
Since the explanted materials are also highly calcified, it is possible that the accumulation of
calcium is correlated with a loss of hydroxyproline since calcium deposits could add weight to the
sample or disrupt collagen structure. To assess this relationship, hydroxyproline content was
plotted as a function of calcium and Pearson’s coefficient was used to measure correlation (Fig.
2.8B). Calcium and hydroxyproline content of rat explants have a strong negative correlation (ρ=0.91). Therefore it is possible that calcification could be responsible for the observed loss of
hydroxyproline.

Fig. 2.8 Hydroxyproline content BP rat subdermal implants. Hydroxyproline levels in nonimplanted and 21 or 90 day explants (A). Correlation between hydroxyproline content and calcium
accumulation (B).
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Weight loss of BHV samples due to collagenase digestion, which was elevated following
oxidation in the accelerated oxidative damage model, was significantly higher in the 21 day BP rat
subdermal explants, but not the 90 day samples (Fig. 2.9A). These results demonstrate that
collagenase digestion may cause degradation of BP in early stages of implantation but appears to
be less damaging in longer-term explants.
Differential scanning calorimetry was used to assess material cross-linking of BP to
determine whether BP rat subdermal explants lose cross-linking during implantation. The shrink
temperature of 90 day rat subdermal implants was significantly lower than the non-implanted BP,
which indicates a loss of cross-linking (Fig. 2.9B).
Picrosirius red staining was done on non-implanted (Fig. 2.9C), 21 day (Fig 2.9D), and 90
day (Fig. 2.9E) rat subdermal explants to assess the degree of collagen damage following
implantation. There were no appreciable differences in the collagen structure between the two
groups. These results suggest that in this model of BHV degradation and at these time points, the
BP structure is not significantly deteriorated.
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Fig. 2.9 Oxidation of BP rat subdermal implants. Weight loss after collagenase treatment (A).
Shrink temperature by DSC (B). Picrosirius red staining non-implanted (C), 21 day explant (D), 90
day explant (E), 200x magnification. *p<0.05 vs non-implanted control.
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Rat subdermal explants of BP from 7 and 21 day experiments were analyzed for
structurally distinct oxidative modification by mass spectrometry to determine if this model
correlates with levels in clinical BHV. The trends of all 6 oxidized amino acid levels correlated with
the clinical BP BHV explants in terms of relatively higher or lower levels in explants as compared
to non-implanted BP (Fig. 2.10). Meta-tyrosine in Glut BP explants was significantly elevated in 21
day explants but not 7 day explants (Fig. 2.10A). Ortho-tyrosine was significantly decreased in 7
day explants but was not significantly different than non-implanted tissue in 21 day explants (Fig.
2.10B). Nitrotyrosine was significantly lower in both 7 and 21 day explants as compared to nonimplanted BP (Fig. 2.10C).

Dityrosine was detectable only in 21 day explants (Fig. 2.10D).

Chlorotyrosine and bromotyrosine levels in explants were not significantly different than nonimplanted BP (Fig. 2.10E-F). All 6 adducts were analyzed although the clinical BHV explants
suggested that only dityrosine was specific to BHV oxidation in order to determine whether the
oxidation pathways involved were different in the rat model. Dityrosine was only present in 21 day
explants and at very low levels as compared to the clinical BHV explants. Therefore, these results
suggest that 21 day rat subdermal implants have modest oxidation, but longer time points or
alternative animal models may more closely recapitulate the clinical BHV oxidation results.
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Fig. 2.10 Oxidized amino acids in BP rat subdermal explants. (A) Meta-tyrosine (B) orthotyrosine (C) nitrotyrosine, (D) dityrosine, (E) chlorotyrosine, and (F) bromotyrosine. * p<0.05 vs
non-implanted control.
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Calcification of pre-oxidized BP rat subdermal implants
Since calcification is a significant cause of BHV degradation, we performed a small pilot
study with 5 rats where BHV materials were “pre-oxidized” with H2O2/FeSO4 then implanted for 90
days (Fig. 2.11A). Surprisingly, these samples had nearly no calcium accumulation as compared
to the control tissues that had median calcium levels around 300 µg/mg. In addition, the “preoxidized” samples had lower shrink temperatures prior to implantation, indicating less cross-linking
(Fig. 2.11B). Therefore, this loss of cross-linking by oxidation may be associated with reduced
calcification. However, since the oxidation of the BP samples was performed artificially or at nonphysiologic conditions, this process may not occur in vivo.

Fig. 2.11 Pre-oxidized BP rat subdermal explants. (A) Calcification of 90 day rat subdermal
explants. (B) Shrink temperature of non-implanted control and pre-oxidized materials.
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Inflammation in rat subdermal models
The BHV leaflet material BP had very low dityrosine accumulation in the rat subdermal
implant model, which suggests that BHV oxidation may not be fully represented in this model. Due
to this finding, additional studies were performed to determine whether there is an attenuated
inflammatory response to the implanted materials in this system. Inflammatory cells are the primary
source of ROS/RNS that would oxidize the implanted material therefore a modest inflammatory
response would result in less material oxidation. In the first system, rat subdermal explants of BP
(7, 21, and 90 day) were removed en bloc and stained with H&E to determine cellular recruitment
to the materials (Fig. 2.12A-C). The thickness of the inflammatory capsule between the explant
surface and the muscle layer was quantified with ImageJ using 40x images. The inflammatory
capsule is thickest in the 21 day explants but also present in the 7 day explants (Fig 2.12D). The
90 day explants do not appear to have a cellular inflammatory capsule but rather more organized,
potentially fibrous tissue (Fig. 2.12C); therefore the thickness of the capsules were quantified only
in the 7 and 21 day explants. These results demonstrate a robust acute inflammatory response to
the BP explants at the 7 and 21 day time points; however, by 90 days, the presence of inflammatory
cells seems to be replaced by the formation of fibrous tissue. These results demonstrate a robust
inflammatory response to BP in the rat subdermal implant model.
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Fig. 2.12 Cellular capsule in en bloc rat subdermal explants. Hematoxylin & eosin staining of
7 day (A), 21 day (B) and 90 day (C) rat subdermal BP explants, 100x. Quantification of thickness
capsule by image analysis in ImageJ of 7 day and 21 day explants (D).
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Longitudinal sections of BP rat explants were analyzed to determine the localization of
inflammatory cells. The highest concentration of cells was found to be at the surface of the material
(Fig. 2.13A). The percent area of hematoxylin staining was much lower for all non-surface sections
(Fig. 2.13B-E). This suggests that there is very little infiltration of cells into the BP explant and
subsequently, that most oxidation is likely to occur on the surface of the material.

Fig. 2.13 Localization of inflammatory infiltrate in en bloc rat subdermal explants. H&E stains
on serial sections of 7 day BP explants. Serial explants are separated by approximately 300 um,
covering the full area of the explant where A is the top surface (0) and E is the bottom surface (1.2
mm), 200x magnification. Quantification of hematoxylin staining in each section (F).
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En bloc BP rat subdermal explants were stained for myeloperoxidase (MPO) to assess the
presence of an ROS/RNS producing enzyme at the surface of the material. Three biological
replicates were imaged at 40x, 100x, and 200x magnification to determine the localization of MPO.
MPO, stained brown with DAB, is present along the outer edge of the explanted material and is
both intra and extracellular (Fig, 2.14A-C).

Co-localization of MPO with the cellular layer

surrounding the explant is apparent with the hematoxylin counterstain. These results demonstrate
MPO staining on the surface of the BP explants.

Fig. 2.14 MPO in 21 day rat subermal explants. (A) 40x (B) 100x (C) 200x.
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To further assess the inflammatory response to BP rat subdermal explants, en bloc
sections were stained with Masson’s Trichrome to visualize the fibrous capsule. The longer time
point explants (21 and 90 day) were used in this study since the formation of a fibrous capsule
occurs later in the foreign body reaction. The formation of a fibrous capsule is evident in both the
21 day and 90 day explants, with the 90 day explants having a much thicker capsule (Fig. 2.15).
These results demonstrate that the rat subdermal implant model with BP recapitulates the later
phase of the foreign body reaction.

Fig. 2.15 Fibrous capsule of rat subdermal explants. (A) 21 day explants (B) 90 day explants,
100x, * indicates fibrous tissue. (C) Quantification of capsule thickness.
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Oxidation and calcification of explants from sheep circulatory model
Since the oxidized amino acid levels in BP rat subdermal explants did not correlate with
the levels found in clinical BHV explants despite the robust inflammatory response, we proposed
that this may be due to a lack of direct circulation exposure as well as mechanical forces. To test
this hypothesis, BJV BHV explants from 3 month sheep pulmonary arteries were analyzed for
oxidized amino acids as well as calcification and morphological changes to determine the type of
structural degeneration affecting these materials. Similar to the PAV and BP explants, the collagen
structure of the BJV explants was not significantly deteriorated (Fig. 2.16A-D). Calcification was
assessed qualitatively with Von Kossa staining of explanted BJV cusps (Fig 2.16E-F). None of the
BJV explants displayed significant calcium accumulation. These results indicate that the BJV
explants were not highly degraded, either by calcification or collagen damage.

Fig. 2.16 Sheep pulmonary artery BJV BHV explant morphology and calcification. Masson’s
trichrome staining of non-implanted BJV (A) and BJV explant (B). Picrosirius red staining of nonimplanted BJV (C) and BJV explant (D). Von Kossa staining of non-implanted BJV (E) and BJV
explant (F).
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Oxidized amino acids were quantified in explants to determine if these explants had higher
levels of oxidized amino acids than subdermal explants.

The main adduct of interest was

dityrosine, however, the whole panel of 6 oxidized amino acids were analyzed for comparison.
Meta-tyrosine, nitrotyrosine, and bromotyrosine were lower in explanted materials than in nonimplanted BJV (Fig. 2.17A, C, F). Ortho-tyrosine and chlorotyrosine were higher in explanted
materials (Fig. 2.17B, E). Similar to the clinical BP and PAV BHV explants, dityrosine was only
detectable in the explanted materials and at levels that correlated with the clinical explants (Fig.
2.17D). These results demonstrate that dityrosine is accumulated in these circulatory explants
therefore suggesting that circulation exposure is involved in the oxidation of BHV.
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Fig. 2.17. Sheep pulmonary artery BJV BHV explants oxidized amino acids. Meta-tyrosine (A),
ortho-tyrosine (B), nitrotyrosine (C) dityrosine (D), chlorotyrosine (E), and bromotyrosine (F) levels
for non-implanted BJV (n=1) and BJV explants placed in sheep pulmonary arteries.
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2.5 Discussion
Clinical BHV explants have an accumulation of dityrosine, thereby supporting the
hypothesis that BHV are susceptible to oxidation. Furthermore, accelerated oxidation of the BHV
leaflet material BP demonstrates that oxidation can lead to structural degeneration including a
breakdown of glutaraldehyde cross-links and an increase in proteolytic degradation. Together
these results demonstrate that oxidative stress affects BHV and contributes to structural
degeneration.
Clinical BHV explants were obtained from patients requiring a replacement aortic valve due
to the failure of the previous BHV. Characterization of these explants demonstrated a high percent
of calcified valves with little or no structural disruption as assessed by morphology. Based on the
high calcium accumulation, it was expected that the collagen structure of the explanted materials
would display disorganization such as fibril fragmentation, but this was not observed. It is possible
that with higher imaging magnification such as transmission electron microscopy, such
fragmentation may be observed despite its absence with light microscopy analysis since it has
previously been documented [72]. These findings are important since they demonstrate that
despite clinical failure and calcium accumulation, there is no significant structural deterioration at
the microscopic level.
The oxidized amino acids meta-tyrosine, ortho-tyrosine, nitrotyrosine, dityrosine,
chlorotyrosine, and bromotyrosine were tested as markers of BHV oxidation since these adducts
are formed through reactions by common oxidants such as hydroxyl radicals and peroxynitrite [84].
In addition, these adducts involve protein oxidation rather than DNA or lipid oxidation; this is
important since BHV materials are primarily protein (collagen) based due to the glutaraldehyde and
ethanol material treatments. Meta-tyrosine and ortho-tyrosine are formed by oxidants capable of
phenylalanine hydroxylation [84]. Nitrotyrosine is a major product of reactions with peroxynitrite
[96]. Dityrosine is formed through tyrosyl radicals, which are the product of various oxidants [78,
83].

Chlorotyrosine is formed through the production of hypochlorus acid by MPO whereas

bromotyrosine is formed from the production of hypobromous acid by eosinophil peroxidase [77,
85]. With the exception of dityrosine, all oxidized amino acids analyzed were present in both non-
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implanted PAV and BP at variable levels. For some oxidation products, such as nitrotyrosine, the
level was lower in the BHV explant as compared to the non-implanted material which would suggest
a reversal of the modification; however, a biochemical process for such a reversal has not been
identified. Due to processing or animal variability, meta-tyrosine, ortho-tyrosine, nitrotyrosine,
chlorotyrosine, and bromotyrosine do not seem to be specific to BHV oxidation that occurs in a
patient. However, for both PAV and BP BHV, dityrosine was not present in the non-implanted
tissues but was elevated in the BHV explants. Dityrosine therefore may be a specific marker of
BHV oxidation. The elevation of dityrosine in the clinical BHV explants demonstrates that both PAV
and BP BHV are subject to oxidation.
Dityrosine, unlike the other oxidized amino acids assessed in BHV explants, is a protein
cross-link that forms as a result of oxidation [83, 97]. In addition to being a marker of BHV oxidation,
dityrosine could represent a functional consequence of BHV oxidation since the introduction of new
material cross-links could alter the mechanical and structural properties of the material. For BHV,
additional cross-linking may cause material stiffening, leading to impaired opening and closing of
the valve and subsequent mechanical failure. However, at this time it is unclear whether dityrosine
represents a functional consequence of BHV oxidation rather than just a marker of BHV
susceptibility to oxidation.
A system of accelerated material oxidative damage was used to examine potential
functional consequences of BHV oxidation. Since BHV structural damage occurs on a time scale
of years it was necessary to develop a system to test oxidation-mediated structural degradation in
an experimental setting. Exposure of BP to oxidizing conditions resulted in significant destruction
of the collagen fibrils as well as mass loss, increased susceptibility to collagenase degradation, and
a loss of glutaraldehyde. Each of these findings could potentially result in structural degradation
and mechanical dysfunction of a BHV. The significant structural deterioration was not surprising
since BHV materials are tissue-derived and these oxidizing conditions greatly exceed physiological
conditions. However, both the collagenase and glutaraldehyde findings are particularly important
since each of these results have been documented in previous studies. Oxidation of soluble or
purified collagen has been shown to increase the susceptibility to proteolytic digestion due to a
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breakdown of collagen cross-linking [28, 30, 31]. Loss of glutaraldehyde cross-linking of BHV
materials has been reported for rat subdermal explants of BP cross-linked with 3H-glutaraldehyde
[98, 99]. Based on evidence of collagenase digestion and loss of glutaraldehyde cross-links, it can
be concluded that oxidation of BHV results in structural degeneration.
The rat subdermal implant model is the widely accepted animal model of BHV calcification
[93, 100]. Juvenile rats are used since they have more active calcium metabolism with higher
circulating levels of alkaline phosphatase as well as calcium and phosphate; therefore contributing
to the accelerated implant calcification [68]. This model was evaluated for its representation of
oxidation-mediated BHV degradation to determine whether it also recapitulates non-calcific BHV
degradation. The mass loss that occurs in the accelerated oxidation model does not occur with rat
subdermal implantation, therefore additional endpoints of BHV oxidation were assessed in the rat
explants due to the difference in degree of material damage. Hydroxyproline is an amino acid
found abundantly in collagen and rarely in other proteins, therefore the levels of hydroxyproline in
a BP sample correlates directly with overall collagen content [95]. Hydroxyproline content was
found to be significantly lower in both 21 and 90 day BP rat subdermal explants, which indicates a
loss of collagen. This measurement may not be specific to collagen oxidation since collagen is
also susceptible to degradation by proteolytic enzymes in vivo [23].

In addition, the loss of

hydroxyproline correlated with higher calcium levels, therefore the accumulation of calcium may
also result in a loss of collagen content. Similar to the accelerated oxidation model, collagenase
digestion and picrosirius red were used to analyze BP rat explants. Although 21 day explants did
show an increase in collagenase digestion compared to non-implanted materials, this difference
was not significant. Furthermore, the 90 day explants were less susceptible to collagenase than
21 day explants. This finding may be due to the high calcium content in the 90 day explants which
reduces collagen content and therefore the substrate of collagenase. Material cross-linking was
assessed with DSC in non-implanted and 90 day BP explants to determine whether there was any
change in overall material stability. Prior to glutaraldehyde fixation, the shrink temperature of BP
is approximately 63 °C [101]. After glutaraldehyde fixation the shrink temperature was 87 °C; the
90 day explants had a shrink temperature of 84 °C, which is significantly lower than the non-
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implanted glutaraldehyde fixed BP, but significantly higher than that of non-glutaraldehyde fixed
BP. The reduction in shrink temperature in the rat subdermal implants from the non-implanted
glutaraldehyde fixed BP could contribute to material failure related to a weakening of the material.
Potentially all of the endpoints assessed for rat subdermal BP implants could lead to material
degradation and eventual failure for BHV.
In order to correlate the rat subdermal model with the clinical BHV explants, oxidized amino
acids were quantified in the BP rat subdermal explants. Previously, we identified dityrosine as the
most reliable marker of BHV oxidation due to its absence in non-implanted materials; however, the
whole panel of oxidation products were quantified in rat explants to fully characterize these
explants. For meta-tyrosine, ortho-tyrosine, bromotyrosine, nitrotyrosine, and chlorotyrosine the
trends seen with the clinical BHV were similar with the BP explants. Dityrosine was present in 21
day but not 7 day explants and at levels a magnitude lower than the clinical values. Together with
the previous oxidation assessment of rat subdermal explants, the dityrosine results indicate that
the rat subdermal implant model does not correlate well with oxidation of clinical BHV explants and
an alternative animal model should be used.
In order to explain how the rat subdermal implant model represents BHV calcification but
not oxidation, additional studies were performed to focus on BP inflammation in this model. We
hypothesize that the major factor of BHV oxidation is the production of ROS/RNS from inflammatory
cells, therefore, this model would need to produce a robust inflammatory response. The results of
the inflammation studies demonstrated an active inflammatory response characterized by cellular
recruitment, MPO, and fibrous capsule formation. Therefore, since the rat subdermal implant
model does involve significant implant inflammation there must be other factors that drive BHV
oxidation such as blood contact or exposure to mechanical stresses.
The availability of BJV BHV explants from a 3 month sheep circulatory model allowed for
the assessment of two critical factors of BHV oxidation: direct blood flow and mechanical forces.
The BJV BHV explants analyzed were obtained from three months old sheep studies of catheterdeployed BHV in the pulmonary arteries. These BJV BHV explants had dityrosine levels similar to
the clinical BHV explants despite the short implantation period. A comparison of the rat and sheep
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model therefore demonstrates that circulation is necessary for BHV oxidation since dityrosine levels
were very low in the rat model. The rat subdermal implant model lacks direct blood flow and
mechanical forces that BHV normally experience. Since exposure to shear stress has been found
to increase oxidative damage [86, 87], it is likely that both direct circulatory exposure and shear
stress are involved in BHV oxidation. Therefore, a short-term circulatory model may be the most
useful system for studying BHV oxidation in a non-clinical setting.
Clinical BHV explants are susceptible to oxidative stress as indicated by the elevation of
dityrosine. Oxidation of the BHV material BP in an accelerated system demonstrated that oxidation
can lead to material degradation including collagen deterioration, loss of glutaraldehyde cross-links,
and an increase in degradation by proteolytic enzymes. Although the rat subdermal implant model
results in an inflammatory response to the BP implant, the oxidation endpoints are only modestly
represented.

However, in a short term sheep circulatory model, oxidation of BJV BHV was

observed, which supports the hypothesis that in addition to inflammation, shear stress, and direct
circulation exposure accelerate BHV oxidation.

Since BHV have the advantages over the

alternative mechanical valves of a lower risk of device-associated thrombosis, significant emphasis
has been placed on improving BHV durability with a specific focus on calcific structural
degeneration.

Although BHV inflammation has been characterized, previous studies did not

address mechanisms of ROS/RNS induced BHV degeneration resulting from the activation of
inflammatory cells. Therefore, these studies identify a previously overlooked mechanism of BHV
structural degeneration arising from oxidation-mediated material damage.
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Chapter 3: Covalent modification of BHV with DBP to mitigate BHV oxidation
This chapter has been published:
Christian AJ, Lin H, Connolly JM, Alferiev IS, Ferrari G, Hazen SL, Ischiropoulos H, Levy RJ. The
susceptibility of bioprosthetic heart valve leaflets to oxidation. Biomaterials. 2014; 35:2097-102.
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3.1 Abstract
Clinical BHV are subject to oxidative modification that can lead to structural degeneration
through the loss of material cross-linking and increased degradation by proteolytic enzymes. We
hypothesized that this process could be mitigated by modifying BHV materials with an antioxidant
to prevent the reaction of oxidants with the material. The oxidant scavenger 3-(4-hydroxy-3,5-ditert-butylphenyl) propyl amine (DBP) was covalently immobilized to BP through a carbodiimidedriven conjugation reaction. DBP attachment to BP, which was confirmed with

14C

labeled DBP,

did not affect mechanical properties of BP. The ability of DBP to mitigate oxidative degradation of
BP was assessed through exposure of BP and DBP modified BP to oxidizing conditions (1%
H2O2/100 µM FeSO4) as well as in a rat model of BHV degeneration. With exposure to oxidizing
conditions, DBP effectively reduced BP oxidative degradation as measured by loss of
glutaraldehyde cross-links and susceptibility to collagenase digestion. In the rat subdermal implant
model, DBP attenuated the reduction of material cross-linking associated with implantation, but did
not affect the accumulation of oxidized amino acids including dityrosine, which was only modestly
elevated in the explanted materials. In addition, DBP modified BP had significantly less calcium
accumulation as compared to unmodified explants. These studies demonstrate that modification
of BHV materials with the oxidant scavenger DBP mitigates BHV degradation resulting from
material exposure to oxidizing conditions and may prevent BHV degradation associated with
calcification and oxidation in the rat subdermal implant model.
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3.2 Introduction
BHV are susceptible to oxidative stress, as indicated by elevated dityrosine in clinical BHV
explants and structural degeneration resulting from exposure to oxidizing condition, which includes
loss glutaraldehyde cross-links and increased digestion by proteolytic enzymes [102]. Strategies
to prevent or mitigate oxidation-mediated structural degeneration of BHV have not been developed.
In these studies we investigated the hypothesis that modification of BHV materials with an oxidant
scavenger could prevent structural degeneration resulting from oxidative stress.
Studies with polymeric biomaterials, such as polyurethane, have demonstrated that
antioxidant material modifications can attenuate material oxidative degradation [27, 33-35]. A
common approach for modifying a polymeric biomaterial with an antioxidant is to dissolve the
compound, such as α-tocopherol or Santowhite, in the polymer solution prior to casting [33]. In
addition, surface modifications of the polymer have been done following casting through covalent
modification such as bromoalkylation of the polymer followed by a reaction with a thiol-containing
antioxidant [27]. It may be possible to use a variation of both methods, either passive incorporation
by incubating the material in a solution containing the antioxidant or covalent modification, to modify
BHV materials with an antioxidant. Covalent modification was tested as our first approach for
modifying BHV materials to create a model oxidation resistant material, which was chosen based
on the experience in the Levy lab with this type of modification of biomaterials.
Glutaraldehyde-fixed heterograft tissues are used in the fabrication of BHV.

These

materials are comprised primarily of collagen and other extracellular matrix proteins. Due to the
composition of these materials, there are some limitations in the types of conjugation chemistries
that could be used to attach an antioxidant. The functional groups found in collagen are amines
from lysine and asparagine, and carboxylic acids from glutamate and aspartate [103]. In addition,
harsh solvents cannot be used since they would severely damage the tissue. Amines are involved
in glutaraldehyde cross-linking [40], therefore carboxylic acids are the available functional groups
for conjugation. We first aimed to covalently link an antioxidant containing a reactive amine to
carboxylic acids of the BHV materials through a carbodiimide-driven reaction.
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The requirements of an antioxidant for conjugation through carbodiimide-driven chemistry
are a reactive amine that is not necessary for antioxidant activity and compound stability at slightly
acidic pH which is used in the carbodiimide activation of carboxylic acids. Based on previous
studies by the Levy lab with di-tert-butylphenol derivatives [27, 36], which are based on the
commercially used antioxidant BHT, we proposed the use of an analogue of these compounds
containing the appropriate reactive amine. The compound must contain an accessible amine
therefore an alkyl chain and terminal amine were added to the compound, resulting in the
compound 3-(4-hydroxy-3,5,-di-tert-butylphenyl)propyl amine (DBP).
DBP was reacted with the BHV material BP according to the proposed carbodiimide-driven
reaction to determine the efficiency of DBP conjugation to BP. In addition, DBP modified BP was
characterized in terms of mechanical properties as well as oxidant scavenging capacity of DBP in
order to assess whether the modification chemistry had any negative impact on BP or DBP. To
address our initial hypothesis that BHV materials modified with DBP would be less susceptible to
oxidative degradation, BP with and without DBP was assessed for oxidative degradation resulting
from either exposure to oxidizing conditions or subdermal implantation in rats.
Here we developed an antioxidant modification of the BHV material BP using DBP, which
is structurally-similar to BHT, and a carbodiimide-driven conjugation reaction for immobilization of
DBP to the carboxylic acid groups of BP. DBP modified BP was assessed for material properties
and resistance to oxidative damage.
3.3 Materials and Methods
Materials
Biosol and Bioscint were purchased from National Diagnostics (Atlanta, GA). Amplex Red
was purchased from Life Technologies (Philadelphia, PA). Glutaraldehyde was purchased from
Polysciences, Inc (Warrington, PA).

3H-glutaraldehyde

and [2,3-14C]-methyl acrylate were

purchased from American Radiolabeled Chemicals (St. Louis, MO). All chemicals unless otherwise
specified were purchased from Sigma Aldrich (St. Louis, MO).
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Synthesis of DBP
DBP was synthesized by Dr. Ivan Alferiev through the reaction of 2,6-di-tert-butylphenol
with methyl acrylate under catalysis with a mixture of NaOH and KOH. The resulting methyl 3-(4hydroxy-3,5,-di-tert-butylphenyl)propionate was reduced with lithium aluminum hydride in ethyl
ether to 3-(4-hydroxy-3,5,-di-tert-butylphenyl)propanol, which was transformed into the mesylate
by treatment with methanesulfonyl chloride and triethylamine in dichloromethane. The mesylate
was reacted with phthalimide potassium salt in 1-methylpyrrolidinone and the phthalimide
derivative was cleaved with hydrazine in ethanol to DBP-amine base, which was finally transformed
into its water-soluble hydrochloride (Fig. 3.1).

Fig. 3.1 DBP synthesis. The synthesis of DBP from the precursor 2,6-di-tert-butylphenol.
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14C-DBP

hydrochloride (7 μCi/mmol) was prepared similarly to non-labeled DBP, using

[2,3-14C]-methyl acrylate (10 – 20 mCi/mmol) diluted with the non-labeled compound. The only
difference between this radiolabeling synthesis and the non-radioactive procedure was at the first
step, where an excess of 2,6-di-tert-butylphenol was applied to react the labeled acrylate as
completely as possible.
BP treatments and DBP modification
Fresh BP obtained from an abattoir was treated with 0.625% glutaraldehyde or 0.625% 3Hglutaraldehyde (specific activity 24 µCi/mmol) in HEPES buffer pH 7.4 for 7 days at room
temperature with gentle shaking. BP was then modified with DBP through a carbodiimide-driven
conjugation reaction (Fig. 3.2). The DBP modification reaction was prepared as two solutions: 42
mM DBP in 100% ethanol and 43 mM N-hydroxysuccinimide (SuOH) in deionized H2O.
Immediately before adding BP, the two solutions were combined and 65 mM 1-ethyl-3-(3dimethylaminopropyl)carbodiimide hydrochloride (EDC) was added. The reaction proceeded for 24
hours at room temperature with gentle shaking. DBP modified BP was rinsed for 10 minutes in
100% ethanol to remove precipitate formed during the reaction. The required length of the ethanol
rinse was determined experimentally through UV monitoring of the wash solution; the precipitate is
rapidly solubilized in ethanol, therefore only a short reaction time is necessary. As a control for the
effects of DBP, BP was treated with the carbodiimide reaction with the exclusion of DBP (GlutEDC/SuOH). All BP samples were stored in 0.2% glutaraldehyde.
C(CH3)3
OH
OH
(H3C)3C

COOH

Collagen fiber

EDC, SuOH
50% EtOH
pH ca. 5.5

COOSu

Collagen fiber

C(CH3)3

O

C(CH3)3

NH

H2 N
Collagen fiber

Fig. 3.2 DBP modification scheme. Carboxylic acids are activated with the carbodiimide EDC in
the presence of SuOH to form stable N-succinimidyl ester intermediates that can then react with
the amine of DBP to form an amide bond.
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Glutaraldehyde fixed BP was reacted with [bis(trifluooacetoxy)iodo]benzene (BTI) to
convert asparagine (Asn) and glutamine (Gln) residues to diaminopropionic acid and
diaminobutanoic acid, respectively, and prevent the conversion of Asn to aspartic acid (Asp) and
Gln to glutamic acid (Glu) during acid hydrolysis [104]. BTI derivatization was performed in 5 M
guanidine-HCl and 10 mM trifluoroacetic acid for 4 hours at 60ºC [105]. BP was then hydrolyzed in
6 N HCl, dried under air at 60 °C, and reconstituted for amino acid analysis by HPLC at the CHOP
Metabolomics Core Facility.
BP was modified with

14C-DBP

attachment of DBP to BP. Lyophilized

through the carbodiimide-driven reaction to quantify the

14C-DBP

modified BP was solubilized with Biosol at 50 °C

with shaking for 72 hours. Solubilized tissues were added to Bioscint and analyzed by liquid
scintillation counting.
Material properties of DBP BP
Material cross-linking of DBP modified pericardium was determined using differential
scanning calorimetry (DSC) to measure thermal denaturation temperature [91]. A 2 mm tissue
biopsy punch was used to prepare pericardium samples for DSC analysis. The samples were
hermetically sealed in aluminum pans then analyzed using a Perkin Elmer DSC 7. The sample
temperature was increased from 25 °C to 100 °C at 10 °C/min. The endothermic peak was
calculated using Pyris software.
DBP modified pericardium was subjected to uniaxial tensile testing to determine the effects
of the DBP modification on material flexibility and strength. Samples were cut to dimensions of 8
mm width and 25 mm length. Semi-circular sections were cut from the middle of the sample to
obtain a bone-like shape. The samples were tested using an Instron machine with assistance from
Dr. Alex Radin at the University of Pennsylvania. The samples were placed in pneumatic grips and
stretched at a crosshead speed of 100 mm/min until failure. Young’s elastic modulus, ultimate
tensile strength, and maximum elongation were determined from the load-displacement data
obtained during testing.
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Oxidation capacity of DBP BP
The oxidation reporter molecules dihydrorhodamine 123 (DHR123) and Amplex Red were
used to determine the oxidant scavenging capacity of DBP modified BP in a system containing
MPO (1 µg/mL), H2O2 (10 µM), and either Cl- (120 mM NaCl) or NO2- (100 µM NaNO2) ions [106].
Amplex red (50 µM) or DHR123 (25 µM) was added to the BP samples immediately after adding
H2O2, MPO and either NaCl or NaNO2. Fluorescence of the solution was determined 30 minutes
after adding Amplex Red or DHR123 in order to quantify the corresponding oxidation products
resorufin or rhodamine, respectively.

Fluorescence was measured an excitation/emission of

560/590 nm for resorufin and 536/500 nm for rhodamine.
For a cell-based system of oxidation, HL-60 (ATCC) were differentiated to a neutrophil-like
phenotype in 1.25% DMSO in IMDM/20% FBS/penicillin/streptomycin for 3 days at 37 °C in 5%
CO2 [107-109]. Differentiated HL-60 (1 x 105 cells) were seeded on 4 mm BP samples in a solution
containing 4 U/mL horseradish peroxidase, 5 µM Amplex Red or DHR123, and 500 ng/mL
phorbolmyristylacetate (PMA). Resorufin or rhodamine fluorescence was read 30 minutes after
the addition of PMA.
Accelerated oxidative damage model
BP samples were placed in PBS or 1% H2O2/100 µM FeSO4 for 7 days with solution
changes every 2-3 days. Lyophilized samples were weighed at the start and end of treatments.
The same endpoints described in Chapter 2 were used to assess the effect of DBP in this system.
Rat subdermal implants
Three week old male Sprague-Dawley rats (60-90 grams) were used for the subdermal
implantation studies as previously described in Chapter 2. The animals were sacrificed at 7, 21, or
90 days and the materials were explanted for further analysis. The implants were removed and
either fixed in neutral buffered formalin for paraffin embedding or acid hydrolyzed for calcium
analysis. Heparinized blood was taken from rats at the 90 day time point to measure toxicity.

62

Toxicity
Toxicity was assessed by measuring levels of alkaline phosphatase (ALP), creatinine, and
aspartate transaminase (AST) in plasma of rats with implants for 90 days [110, 111]. Creatinine
was measured using a creatinine assay kit (Cayman Chemical). AST was measured with the
Abnova AST kit. ALP activity was through a reaction of serum samples with the ALP substrate pnitrophenylphosphate disodium salt hexahydrate (10 mM); the formation of p-nitrophenol was
monitored by absorbance and compared to a standard curve of p-nitrophenol. All kits were used
according to manufacturer instructions
Statistical Methods
Results are shown as the mean ± standard error for the mean. Single ANOVA with Tukey’s
test or a two tailed t-test were used to determine significance, which was defined as a p value less
than 0.05.
3.4 Results
Attachment of DBP to BP
To estimate the maximum binding capacity of DBP to BP, total amino acid composition
was determined by HPLC (Fig. 3.3A). The major amino acids of BP are glycine, alanine, and not
measured here, proline and hydroxyproline [103]. Since the carbodiimide reaction involves the
activation of carboxyl in BP, the molar concentration of Asp and Glu residues in acid-hydrolyzed
BP samples is of importance to the theoretical maximum binding of DBP to BP. A BTI derivatization
step was included for quantification of Asp and Glu in order to convert asparagine (Asn) and
glutamine (Gln) residues to diaminopropionic acid and diaminobutanoic acid, respectively, and
prevent the conversion of Asn to aspartic acid (Asp) and Gln to glutamic acid (Glu) during acid
hydrolysis. There are 196 ± 7 nmol Asp/mg dry BP and 303 ± 10 nmol Gln/mg for a total of 499 ±
17 nmol of terminal carboxyl-containing amino acid residues per mg of BP (Fig. 3.3B). Therefore
the maximum attachment of DBP is 500 nmol/mg based on amino acid composition.

63

Fig. 3.3 Amino acid composition of BP. (A) Full amino acid composition (B) Asp and Glu
quantification with BTI derivatization.
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The attachment of DBP to BP was quantified using 14C-labeled DBP. A dose curve of DBP
modified BP was generated through dilutions of the DBP reaction solution in 50% ethanol (Fig. 3.4).
The amount of DBP attached to BP using the undiluted reaction solution was 439 ± 8 nmol/mg.
This result demonstrates that the reaction of DBP with BP results in nearly maximum attachment
of DBP to BP based on the predicted binding determined by Asp and Glu quantification.

Fig. 3.4 14C-DBP binding to BP. Dose curve generated by dilution of reaction components in 50%
ethanol.
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Material properties of DBP BP
To assess whether the DBP modification affects the material properties of BP, uniaxial
tensile testing and DSC were performed on unmodified and DBP modified BP. A representative
stress-strain curve is shown for both groups (Fig. 3.5). Ultimate tensile strength, maximum strain,
and Young’s elastic modulus were calculated from tensile testing. The tensile properties of DBP
modified BP did not differ significantly from unmodified BP (Table 3.1). The shrink temperature of
pericardium was not affected by the DBP modification (Table 3.1). These results demonstrate that
the DBP modification does not change the material properties of BP.

Fig. 3.5 Stress-strain response. Tensile testing of glutaraldehyde fixed BP with and without the
DBP modification. Representative curves shown for n=5.

Table 3.1. Mechanical properties of BP. Shrink temperature determined by differential scanning
calorimetry. Elastic modulus, ultimate tensile strength, and elongation determined from stressstrain curves generated from tensile tests.
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Oxidant scavenging capacity of DBP BP
The oxidation reporter molecules Amplex Red and DHR123 were used to determine the
oxidant scavenging capacity of DBP modified BP. Oxidants generated by MPO in the presence of
hydrogen peroxide and either chloride or nitrite or by PMA activated HL-60 were used to oxidize
Amplex Red to resorufin and DHR123 to rhodamine. Significantly less Amplex Red and DHR123
were oxidized in the presence of DBP modified BP as compared to unmodified BP in the cell-free
systems (Fig. 3.6), which demonstrates that DBP scavenges oxidants after immobilization to BP.
In the HL-60 ROS/RNS producing system, DBP modified BP had less oxidation of both Amplex
Red and DHR123, but these differences were not significant which could be due to biologic
variability or for DHR123, intracellular oxidation since DHR123 crosses the cell membrane. These
results demonstrate that DBP modified BP has oxidant scavenging activity.
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Fig. 3.6 Oxidant scavenging capacity of DBP modified BP. MPO/H2O2/Cl oxidation of Amplex
red (A) and DHR123 (B). MPO/H2O2/NO2 oxidation of Amplex red (C) and DHR123 (D). HL-60
respiratory burst oxidation of Amplex red (E) and DHR123 (F). * p<0.05 vs unmodified (Glut) BP.
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DBP mitigates BP oxidation in experimental oxidizing conditions
Previously it was shown that oxidation of BP by a well-known oxidizing system results in
significant material destruction as shown by picrosirius red staining, material weight loss,
collagenase digestion, and loss of 3H-glutaraldehyde cross-links (Fig. 2.3). When exposed to the
same oxidizing conditions, DBP modified BP had significantly less oxidative damage than
unmodified BP as shown by picrosirius red staining (Fig. 3.7A-D) and total mass loss, 20.2 ± 2.6%
dry weight loss vs. 94.1 ± 0.8% (Fig. 3.7E). DBP modified BP was also less susceptible to digestion
by collagenase than unmodified BP (p = 0.01) (Fig. 3.7F) and had decreased release of 3Hglutaraldehyde than unmodified BP (p < 0.01 (Fig. 3.7G). For all endpoints, the chemically treated
BP control (Glut-EDC/SuOH) had no effect on preventing oxidative damage thereby demonstrating
that DBP rather than the carbodiimide-driven conjugation reaction is responsible for the attenuation
of material oxidative damage.
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Fig. 3.7 BP oxidation with H2O2 and FeSO4. (A-D) Picrosirius red staining of collagen (A) Glut
pericardium no treatment (B) Glut pericardium oxidized (C) Glut-EDC/SuOH oxidized (D) Glut-DBP
oxidized (E) Dry weight loss of pericardium (F) Collagenase treatment of oxidized pericardium. (G)
Stability of 3H-glutaraldehyde cross-linking in PBS and oxidizing conditions. 3H-glutaraldehyde
released into solution and 3H-glutaraldehyde bound to tissue at end of treatments. * p < 0.05 vs
Glut.
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Toxicity
Systemic toxicity of DBP modified BP was assessed through measurement of ALP, AST,
and creatinine in serum of rats with 90 day BP implants. ALP, AST, and creatinine levels from rats
with unmodified BP implants were within or slightly below the reported normal range [110, 111],
indicating that the presence of BP alone does not cause systemic toxicity. Both DBP modified BP
(Glut-DBP) and carbodiimide reacted BP (Glut-EDC/SuOH) did not cause a significant change in
serum ALP, AST, or creatinine (Table 3.2), thereby demonstrating that the DBP modification does
not cause systemic toxicity in rats. In addition to the DBP modified and chemistry control samples,
the ethanol groups (Glut-EtOH (10 min), Glut-EtOH, and Glut-DBP-EtOH), which were included to
assess calcification did not cause systemic toxicity.

Table 3.2 Toxicity in rat subdermal implant model.
subdermal BP implants for 90 days.

Serum toxicity markers in rats with
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Calcification
Calcification of BP was assessed in 21 day and 90 day rat subdermal explants to determine
the effect of the DBP modification on calcium accumulation since calcification is a significant cause
of structural deterioration of BHV. BP that was exposed to 100% ethanol (Glut-EtOH) was used as
a positive control for mitigating BHV calcification since this material treatment is used in some
clinical grade valves [79]. The DBP modification involves carbodiimide-driven chemistry as well as
exposure to ethanol, therefore additional experimental groups were included in this study to control
for anti-calcification effects of either the chemistry or ethanol. The mean calcium level in Glut BP
explants was 59.4 ± 10.0 µg calcium/mg tissue for 21 day explants (Fig. 3.8A) and 334.6 ± 24.8 µg
calcium/mg tissue for 90 day explants (Fig. 3.8B). Calcium levels were significantly lower than Glut
for Glut-EtOH 10 minutes, Glut-EtOH, and Glut-DBP-EtOH 21 day explants (p<0.05). Glut 21 day
explant calcium levels were higher than those of Glut-DBP and Glut-EDC/SuOH (30.3 ± 1.5 µg
calcium/mg tissue and 31.9 ± 8.9 µg calcium/mg tissue, respectively), but these differences were
not statistically significant. The 21 day results indicate that ethanol exposure provides more
resistance to calcification than the DBP modification or carbodiimide chemistry, but these
treatments also reduced calcium accumulation. In 90 day explants, Glut-DBP, Glut-EDC/SuOH
(carbodiimide chemistry control), and Glut-DBP-EtOH had significantly lower calcium levels than
Glut, but Glut-EtOH did not (Fig. 3.8B). Interestingly, the fold increase in calcium from 21 to 90
days was significantly higher in the Glut-EtOH group as compared to all other experimental groups
(Fig. 3.8C). This result demonstrates significant breakthrough calcification for this clinically-used
anti-calcification strategy. Interestingly, the DBP modification and carbodiimide control did not
demonstrate this significant increase in calcification from 21 to 90 days. These results demonstrate
that the DBP modification mitigates calcification of BP, but this effect may be due to the
carbodiimide chemistry and ethanol exposure rather than the antioxidant activity of DBP.
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Fig. 3.8 Calcification in rat subdermal implant model. 21 day (A) and 90 day (B) explants. Fold
change in calcium levels from 21 to 90 days.

73

Oxidation
Several endpoints were used to assess BHV oxidation, including hydroxyproline loss,
collagenase digestion, shrink temperature, and oxidized amino acids. We previously demonstrated
that 90 day BP explants have a significant loss of hydroxyproline, indicating a loss of collagen
content. This effect may result from oxidation as well as proteolytic degradation or calcification.
Hydroxyproline content was assessed in DBP modified BP explants in order to assess whether
DBP has a protective effect against collagen loss.

Neither DBP nor the EDC/SuOH control

mitigated the loss of hydroxyproline (Fig. 3.9A) thereby demonstrating that DBP does not
specifically prevent collagen loss.
Collagenase digestion was significantly increased in BP following exposure to oxidizing
conditions, therefore this endpoint was used as a measure of oxidation in 90 day BP explants. The
90 day BP explants were more susceptible to collagenase digestion than non-implanted control
tissue, but this difference was not significant by ANOVA (p=0.075) (Fig. 3.9B). DBP BP explants
were less, but not statistically significant, susceptible to collagenase digestion than unmodified and
carbodiimide reacted BP (Glut 13.5 ± 1.8, Glut-DBP 8.1 ± 1.6, Glut-EDC/SuOH 10.4 ± 2.9) (Fig.
3.9C). These results indicate that although the 90 day explants are slightly more susceptible to
collagenase digestion than non-implanted materials, DBP does not have a significant effect on
proteolytic degradation.
Shrink temperature, as determined by DSC, is used as a measure of material cross-linking,
which could be disrupted by oxidative stress. Therefore, the shrink temperatures of BP explants
were assessed to determine whether this endpoint could be used as an in vivo marker of oxidative
stress. Unmodified (87.1 ± 0.5 °C control vs 84.4 ± 0.6 °C explant)and carbodiimide reacted BP
(90.1 ± 0.1 °C control vs 87.4 ± 0.1 °C explant) had significantly lower shrink temperatures than
non-implanted controls (p=0.031 and p=0.0012, respectively). The shrink temperatures of nonimplanted DBP and DBP explants were not significantly different (p=0.65) (Fig. 3.9C). These
results demonstrate that BP material cross-linking is affected during implantation as indicated by a
decrease in shrink temperature and DBP can mitigate this effect, thereby demonstrating a
protective effect in vivo.
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Fig. 3.9 Oxidation of rat subdermal explants. Loss of hydroxyproline in 90 day explants as
compared to non-implanted BP (control) (A). Collagenase digestion of 90 day explants and nonimplanted BP (B). Shrink temperature differences between controls and explants (C). * p<0.05 vs
control.
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In previous studies, the levels of oxidized amino acids in 7 and 21 day rat subdermal
implants were shown to be only mildly elevated as compared to non-implanted materials (Fig. 2.5).
However, since it was not feasible to test the effect of the DBP modification in a different animal
model, such as a sheep circulatory implant, the rat subdermal implant model was used to assess
the effect of DBP on this oxidative endpoint. Dityrosine levels are shown for the rat subdermal
explants since this adduct was found only in clinical BHV explants and not in control non-implanted
tissues. Dityrosine was detected in some but not all 21 day explants; 3 of the 5 DBP modified
explants had measurable levels of dityrosine (Fig. 3.10). Due to the low levels of dityrosine in the
explants, it was not possible to fully assess whether DBP had an effect on the accumulation of this
adduct.

Fig. 3.10 Dityrosine in rat subdermal explants. Dityrosine levels in 7 and 21 day Glut-DBP and
Glut-EDC/SuOH rat subdermal explants.
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3.5 Discussion
BHV have been shown to be susceptible to oxidative degradation; therefore, the use of
antioxidants may prevent BHV degeneration.

As a strategy to mitigate oxidation-mediated

degradation of BHV, the BHV material BP was modified with the antioxidant DBP. After confirming
the attachment of DBP to BP, we demonstrated that the modification does not alter the mechanical
or material properties of BP, which could otherwise affect hemodynamic properties. The oxidant
scavenging activity of DBP following immobilization to BP was characterized, thereby
demonstrating that DBP retains antioxidant activity.

Subsequently, DBP mitigated oxidative

damage of BP in an accelerated model. To translate these findings to an animal model, DBP
modified BP was subject to the rat subdermal implant system. DBP attenuates the loss of material
cross-linking normally seen with unmodified BP explants. In addition, DBP combined with the
carbodiimide chemistry and ethanol treatment, reduced the progression of calcification to a greater
extent than ethanol pretreatment alone.

These studies demonstrate that an antioxidant

modification of BHV materials can reduce BHV structural degeneration.
Since previous pretreatment and local delivery strategies for BHV have not involved
incorporation of a compound in the BHV leaflets, a major component of these studies was the
optimization of the reaction used for immobilizing DBP to BP. Carbodiimide-driven reactions have
previously been used in the context of BHV, but for the purpose of additional material cross-linking
rather than immobilizing an active compound such as DBP [39, 45].

The efficiency of the

carbodiimide-driven reaction used to immobilize DBP to BP was assessed by first determining the
theoretical maximal binding of DBP, which is mediated through reactions with carboxylic acids
provided by aspartate and glutamate residues of BP. Aspartate and glutamate composition was
then compared to the actual binding of DBP as determined with

14C

labeled DBP. Based on this

comparison, we determined that the attachment of DBP to BP is nearly maximized. It was therefore
not necessary to further optimize the modification reaction for DBP attachment.
A major advantage of BHV over mechanical prosthetic valves is the blood-material
properties which result in a lower risk of thrombosis [112, 113].

Therefore, any material

modifications involving the BHV leaflet materials should not alter these properties. To demonstrate
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that DBP modified BP leaflets would have similar properties to unmodified BP leaflets, uniaxial
tensile testing was performed. Uniaxial tensile stress is only one of the types of mechanical
stresses affecting BHV leaflets. In addition, BHV leaflets are subject to cyclical flexural and shear
stresses [16, 114]. Only uniaxial tensile testing was performed due to a lack of availability for a
mechanical testing system that could asses all types of mechanical stresses affecting BHV leaflets.
The tensile properties as well as material cross-linking were not affected by DBP, therefore
indicating that the DBP modification would be unlikely to affect hemodynamic properties of a BHV
leaflet. However, future studies should address the performance of DBP modified BHV both under
other forms of mechanical stress such as flow conditions or cyclical fatigue, and ideally in vivo inthe
circulation with blood-material interactions.
The structure of DBP is based on the widely used antioxidant BHT [48]. BHT scavenges
and removes oxidants through oxidation of the hydroxyl group to form phenoxyl radicals that can
be oxidized to various structures through reorganization of the free radical [49]. Since DBP differs
from BHT only due to the addition of a propyl amine, not directly next to the hydroxyl group or the
tert-butyl hindering groups, it is unlikely that the antioxidant activity of these compounds would be
significantly different [115]. However, since DBP is immobilized rather than free in solution, we
confirmed the scavenging activity of DBP following attachment to BP. DBP modified BP has
scavenging activity against both ROS and RNS, which establishes that DBP retains scavenging
activity after immobilization to BP. Multiple oxidant generating systems, including a cell-based
system, were used to demonstrate that DBP is a broad acting oxidant scavenger, which is important
since tyrosyl radicals, which can result in dityrosine formation as found in clinical BHV explants
[102], can be produced by a range of oxidants.
DBP modified BP was subject to an accelerated model of BHV oxidative degradation in
order to determine the ability of DBP to mitigate oxidative damage of BP. DBP mitigated all
parameters of BHV oxidation including collagenase digestion, 3H-glutaraldehyde release, and
general collagen degradation.

This model has previously been used to assess biomaterial

oxidative degradation, but does require the use of non-physiologic conditions, therefore
comparison with additional models should be used. Furthermore, it is striking that DBP was able
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to protect BP from oxidative degradation in this model due to the severity of the oxidizing conditions.
Although additional studies using either animal models or physiologic conditions should be used to
corroborate these findings, the accelerated model of oxidative degradation demonstrated
significant efficacy of DBP in mitigating BP oxidative degradation.
The rat subdermal implant model is one of the established animal systems for testing BHV
degradation. In particular, this model results in accelerated calcification of BHV materials, which
has been shown to be caused by several factors including elevated levels of serum calcium and
phosphorus in juvenile rats as well as higher alkaline phosphatase activity [68]. It has not been
directly studied whether the location of the implant (subdermal) also contributes to accelerated
calcification. Such a study would be technically challenging, if not impossible. As expected for this
model, the unmodified BP implants had significant calcium accumulation at both 21 days and 90
days. Previously these levels have been correlated with mean calcium levels seen in explanted
clinical BHV [68]. Somewhat surprisingly, DBP modified BP rat subdermal explants were less
calcified than unmodified BP at the 90 day time point.

Additionally, the clinically-used anti-

calcification pretreatment of 24 hour ethanol exposure did not have significantly lower calcium
accumulation than unmodified BP at 90 days; thereby demonstrating that the DBP modification
may be superior to ethanol treatment in preventing long-term calcification. However, it is unclear if
DBP alone mitigates BHV calcification, since the chemistry control group also had significantly less
calcium accumulation. The combination of the scavenging activity of DBP and the carbodiimidedriven chemistry may be an effective anti-calcification strategy. Future studies should address
whether oxidation is directly involved with BHV calcification and whether the antioxidant activity or
the carbodiimide-driven chemistry is more important for the anti-calcification effect observed with
DBP modified BP.
Some compounds that have antioxidant activity also possess anti-inflammatory activity due
to the involvement of oxidants in various signaling pathways such as nuclear factor kappa Bmediated production of inflammatory cytokines and subsequent cellular recruitment and activation
[116, 117]. Therefore, we hypothesized that DBP may have an effect on the overall inflammatory
response to BHV leaflets. This hypothesis was tested in the rat subdermal implant model for
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endpoints including cellular recruitment, cytokine production and myeloperoxidase expression
(data not shown).

Unfortunately, we did not observe anti-inflammatory properties for DBP;

therefore suggesting that the major mechanism of action for DBP is its oxidant scavenging
properties.
Oxidation of BHV materials has not previously been assessed by other research groups in
the rat subdermal implant model. Furthermore, the major focus of this system is calcification over
other mechanisms of BHV degeneration. We sought to determine whether this model could
recapitulate the oxidative degradation endpoints we identified in both clinical BHV explants,
specifically dityrosine, or in the accelerated oxidative degradation system. Previously we used
histology to demonstrate a breakdown of BP collagen structure following exposure to oxidizing
conditions. In the rat subdermal implant model, the destruction of the collagen structure was not
as obvious, therefore we added material cross-linking as a measurement of BP degradation.
Unmodified BP explants from the rat model had a loss of material cross-linking as demonstrated
by a decrease in shrink temperature, which was not observed with the DBP modification. This
suggests that DBP may prevent BHV degeneration associated with a breakdown of cross-linking.
Additionally, loss of BHV cross-linking could be associated with calcification progression since the
growth or expansion of calcium phosphate crystals would either breakdown normal material crosslinking, or physically expand in weakened areas due to oxidative damage to crosslinks [13].
Therefore, the DBP effect on cross-linking may also be related to calcification prevention.
Dityrosine formation in rat subdermal BP explants was previously found to poorly correlate
with the levels measured in clinical BHV explants (Chapter 2). However, we did assess the effect
of DBP on dityrosine simultaneously with the unmodified explants. DBP did not affect dityrosine,
which can likely be attributed to the rat subdermal implant model rather than a lack of activity by
DBP since there is only a modest elevation in dityrosine and inconsistently across explants. This
model was used for assessment of DBP in an animal system since it provides a low cost and
technically simple model for testing BHV materials. However, this model lacks direct blood flow
and mechanical forces that BHV normally experience and exposure to shear stress has been found
to increase oxidative damage [87]. In earlier studies, it was shown that the sheep explants had
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dityrosine levels similar to those in clinical BHV explants despite the short implantation period. It
was not possible to test DBP modified BP in a large animal model. Future studies with DBP should
focus on large animal models that involve direct blood contact and exposure to mechanical stress.
Covalent modification of the BHV material BP with DBP mitigated oxidative damage in the
accelerated model. In addition, this modification did not adversely affect the material properties of
BP or the scavenging activity of DBP. Although the covalent attachment of DBP to BHV did not
prevent dityrosine formation in the rat subdermal implant model, it did mitigate calcium
accumulation as well as cross-linking breakdown. Thus, these results demonstrate in both the
accelerated model and the rat subdermal implant model that an antioxidant modification of BHV
materials, specifically with DBP, effectively attenuates structural degeneration associated with
oxidative stress.
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Chapter 4: Attenuation of BHV oxidation with superoxide dismutase mimetics
Manuscript in preparation:
Christian AJ, Garofolo S, Tovmasyan A, Batinic-Haberle I, Bianco R, Ischiropoulos H, Levy RJ.
Mitigation of bioprosthetic heart valve oxidation with a superoxide dismutase mimetic.
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4.1 Abstract
Previously, we demonstrated that the oxidant scavenger DBP is capable of mitigating BHV
oxidation. In order to improve upon the DBP modification strategy, we proposed the use of a class
of catalytic antioxidants, MnPyP SOD mimetics. SOD mimetics such as MnPyP are able to remove
oxidants in a non-stoichiometric manner; therefore, unlike DBP, they may be able to provide
sustained antioxidant protection for BHV. Three MnPyP SOD mimetics, MnTE-2-PyP, MnTnOct2-PyP, and MnTnOct-3-PyP, were compared for use with BHV in terms of efficiency in passive, or
non-covalent, uptake into the BHV material BP. MnTnOct-2-PyP and MnTnOct-3-PyP had greater
retention in BP than MnTE-2-PyP. Since MnTnOct-2-PyP is a more potent SOD mimetic than
MnTnOct-3-PyP, it was identified as the best candidate for use with BHV. In addition, we tested
whether MnTnOct-2-PyP could be packaged in liposomes for targeted drug delivery; based on the
high retention of MnTnOct-2-PyP in BHV we expected that the compound would be a good
candidate for this purpose. We demonstrated that MnTnOct-2-PyP is efficiently incorporated into
liposome drug carriers. MnTnOct-2-PyP loaded BP was tested in the rat subdermal implant model
as well as in a sheep circulatory model to assess its effect on BP degradation. Calcification, which
remains a significant issue with BHV durability, was not significantly affected by the presence of
MnTnOct-2-PyP in BP. In the sheep patch implant model, which provides both exposure to blood
flow and mechanical forces, MnTnOct-2-PyP demonstrated SOD activity following implantation
which indicates stable retention of MnTnOct-2-PyP in BP. The effect of MnTnOct-2-PyP on BHV
oxidation as measured by dityrosine is pending the completion the analysis of these materials.
These studies demonstrate that MnPyP SOD mimetics can be stably incorporated in the BHV
material BP, as well as liposomes, without covalent or other active conjugation while maintaining
SOD activity and may provide sustained antioxidant protection for BHV.
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4.2 Introduction
Antioxidants such as DBP are limited in their oxidant scavenging capacity since they react
with oxidants in a stoichiometric nature [49].

Compounds such as SOD mimetics scavenge

oxidants through redox cycling of a metal center, undergoing reversible reduction and oxidation
while removing potentially damaging oxidants [62]. This mechanism of redox cycling provides
catalytic activity with the potential for long-term antioxidant activity since the original compound is
not irreversibly reduced or oxidized in the process of removing oxidants. We hypothesized that a
catalytic antioxidant such as an SOD mimetic could improve upon the previous DBP strategy for
mitigating oxidation-mediated BHV degradation by providing sustained antioxidant protection.
SOD has the physiological role of controlling superoxide (O 2-•) concentration by catalyzing
its dismutation into molecular oxygen and hydrogen peroxide [118]. Superoxide is normally formed
through mitochondrial electron leak or by inflammatory and endothelial cells [118]. Superoxide is
involved in various signaling events and in the activation of redox sensitive transcription such as
hypoxia factor 1 (HIF-1) and nuclear factor kappa B (NF-κB) which are involved in processes such
as cellular proliferation and neutrophil recruitment and activation [62, 63, 119]. In situations of
excessive superoxide production such as in acute inflammation, without removal by SOD,
superoxide could cause damage to DNA, lipids, or proteins [118]. Superoxide is capable of
oxidative protein fragmentation at proline residues, which is relevant to the degradation of BHV
since collagen has a significantly higher percent of proline residues (16% of all amino acids) as
compared to the average protein (5.6%) and may therefore be more susceptible to superoxidemediated damage [55]. Although superoxide is able to direct damage proteins [28, 56], it has been
proposed that the major deleterious effects of superoxide overproduction or loss of SOD function
are mediated through the production of other more reactive oxidants from superoxide [55, 118].
Superoxide is involved in the production of peroxynitrite (ONOO-) from nitric oxide [58] as well as
hydrogen peroxide and subsequently hydroxyl radicals through Fenton chemistry[120]. The use of
SOD or an SOD mimetic may effectively mitigate BHV oxidation by controlling the formation of
other oxidants as well as preventing direct damage by superoxide.
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The clinical use of native SOD is limited by its size, susceptibility to proteolytic degradation
leading to a short circulating half-life, antigenicity, and the expense of large-scale protein production
[54]. Due to these limitations as well as the significance of SOD in various disease states including
atherosclerosis, cancer, and amyotrophic lateral sclerosis [62], synthetic compounds that are
capable of mimicking the activity of SOD have been developed. At this time there are numerous
classes of SOD mimetics available. The consistent structural feature of the SOD mimetics is a
redox reactive metal center, typically manganese, iron, or copper [54, 63]. The most potent SOD
mimetics also have a ring structure and cationic substituents to provide electrostatic guidance for
superoxide towards the metal center [62, 64]. SOD mimetics dismutate superoxide through the
same mechanism as native SOD: oxidation M n+1-SOD+ O2-•  Mn-SOD + O2 and reduction MnSOD + 2H+ + O2-•  Mn+1-SOD + H2O2 [62]. Some of the important features of an SOD mimetic are
the reduction potential of the metal center which should equally favor both reduction and oxidation,
the catalytic rate constant for superoxide dismutation, and stability of the metal center [60, 62, 121].
The reduction potential of the metal center for native SOD is +300 mV vs. normal hydrogen
electrode (NHE); this value is nearly evenly between the potential for superoxide oxidation (-160
mV) and reduction (+890 mv), thereby not favoring one reaction [62]. Loss of the metal center can
occur for compounds that favor the oxidation reaction and the lower oxidation state of the metal
[62].
MnPyP are a class of SOD mimetics that have been widely studied and optimized for SOD
activity, lipophilicity, and bioavailability and are therefore good candidates for clinical use. MnPyP
SOD mimetics have additional antioxidant functions including scavenging of peroxynitrite and
peroxyl radicals [54, 64]. A broad acting antioxidant is favorable for use with BHV since there are
a variety of reactive species produced during inflammation and in normal physiology. The MnPyP
SOD mimetics are also capable of scavenging H2O2 [54] by mimicking catalase: Mn(III)-PyP + H2O2
+ 2H+ Mn(IV)-PyP + 2H2O and Mn(IV)-PyP + H2O2  Mn(III)-PyP + O2 + 2H+ [122] or peroxidase
Mn(III)-PyP + H2O2 + AH2  Mn(III)-PyP + A + 2H2O, where A is an oxidizable substrate [123]. The
catalase and peroxidase activity of the SOD mimetics is an important function since H2O2 is
produced through the dismutation of superoxide [62]. Therefore, a specific SOD mimetic that
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lacked any catalase or peroxidase activity could be potentially damaging through this pro-oxidant
activity of producing H2O2 [124]. By using SOD mimetics that can scavenge other oxidants,
particularly H2O2, it may be possible to avoid the deleterious effects of H 2O2 production from
superoxide dismutation.
In addition to antioxidant activity, the MnPyP SOD mimetics are cationic and possess
hydrophobic alkyl chains that may mediate uptake into a tissue such as BP [46, 119]. Hydrophobic
compounds are able to partition through lipid membranes, thereby resulting in higher cellular or
tissue uptake [119]. Thus, a hydrophobic compound such as a MnPyP is expected to have more
efficient uptake into a BHV material. The charge of the compound may also contribute to the
distribution of a compound within a tissue or cell. Collagen contains both negatively and positively
charged residues [125], therefore a charged compound may be able to interact with these regions
to facilitate stable incorporation through ionic interactions. Both electrostatic and hydrophobic
interactions may facilitate uptake and retention into tissues thereby avoiding the use of a
chemically-driven reaction and the exposure to additional reagents that may affect the activity of
the MnPyP or the integrity of the BHV material.
A compound that has efficient uptake into a tissue such as BHV heterograft materials may
also be efficiently incorporated into lipid-based drug carriers or liposomes for targeted drug delivery
[126]. There are numerous applications including solid tumor cancers and inflammatory conditions
in which targeted drug delivery may be advantageous in either altering pharmacokinetic properties,
reducing toxicity, or improving efficacy [127]. In addition, targeted delivery of antioxidants such as
SOD mimetics may be useful in treating conditions involving oxidative stress such as endothelium
dysfunction related to acute lung injury [128-131].
Three manganese pyridyl porphyrin SOD mimetics were provided by the Batinic-Haberle
group of Duke University: MnTE-2-PyP, MnTnOct-2-PyP, and MnTnOct-3-PyP. The two ortho
substituted compounds (MnTE-2-PyP and MnTnOct-2-PyP) have stronger SOD activity than the
meta substituted compound (MnTnOct-3-PyP) as determined by the rate constant for superoxide
dismutation, logkcat, which have been reported as 7.76, 7.71, and 6.53, respectively [61]. In addition
to differences in SOD activity, the compounds also differ in lipophilicity as determined by both the
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thin layer chromatography retention factor (Rf) and the octanol-water partition coefficient (logPOW),
with MnTnOct-3-PyP being most lipophilic (Rf 0.656, logPOW not reported), followed by MnTnOct2-PyP (Rf 0.644, logPOW -2.32), and MnTE-2-PyP (Rf 0.156, logPOW -7.79) [61, 132]. Here we
assessed the incorporation of MnPyP SOD mimetics into the BHV material BP and the effect of
these compounds on BHV oxidation.
4.3 Materials and Methods
Materials
MnTE-2-PyP, MnTnOct-2-PyP, and MnTnOct-3-PyP were provided by Ines BatinicHaberle (Duke University, Durham, NC). Phospholipids were purchased from Avanti Polar Lipids
(Alabaster, AL). All chemicals unless otherwise specified were obtained from Sigma Aldrich (St.
Louis, MO).
Spectroscopy
The manganese pyridyl porphyrin SOD mimetics absorb in the visual spectrum, which
allows for quantification by spectroscopy. The three SOD mimetics tested have a maximum
absorbance at 455 or 460 nm [132, 133]; these wavelengths were used for measuring the
concentration of a compound in solution.
Incorporation of SOD mimetics in BP
BP samples were incubated in aqueous solutions of MnTE-2-PyP, MnTnOct-2-PyP, or
MnTnOct-3-PyP for 18-24 hours overnight at 37 °C with shaking. At the end of the incubation, the
concentration of unreacted compound was determined by absorbance of the reaction solution at
the maximum absorbance, 455 or 460 nm. BP samples that had been incubated with SOD
mimetics were placed in 5 mL PBS for release at 37 °C with shaking. PBS solutions were changed
after 2 and 4 hours then every 24 hours for 5 days at which point no measurable amount of
compound released was measured. A455 or A460 was used to measure the amount of compound
released from BP. The amount of SOD mimetic retained within the BP sample was determined by
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subtracting the amount of compound in the wash steps and 5 day release period from the total
compound reacted. Samples were stored at 4°C in PBS for future use.
SOD activity of drug loaded BP
The nitroblue tetrazolium (NBT) reduction assay was adapted to measure SOD activity of
SOD mimetics incorporated in BP (Fig. 4.1) as previously described [134]. BP samples (4 mm)
were incubated in nitroblue tetrazolium salt (10 mg/mL) for 20 minutes at room temperature. The
samples were then rinsed before adding a solution containing xanthine (59 µM), followed by
xanthine oxidase. The reaction proceeded overnight at room temperature. The samples were
washed and imaged. Image analysis was done with ImageJ. Mean gray value of the images were
used to determine NBT reduction; mean gray value is reported as a fold change from the same
tissue before exposure to NBT.

Fig. 4.1 NBT reduction assay. The reaction of xanthine oxidase with xanthine produces
superoxide as well as uric acid and hydrogen peroxide. NBT is reduced to NBT-diformazan dye in
the presence of superoxide. When superoxide dismutase or SOD mimetics are present, NBT is not
reduced since SOD dismutates superoxide to oxygen and hydrogen peroxide.
Rat subdermal implants
Three week old male Sprague-Dawley rats (60-90 grams) and 1 cm2 BP samples were
used for the rat subdermal implantation studies as previously described [68]. A loading dose of
150 µg MnTnOct-2-PyP was used for each 1 cm 2 BP section. Following the standard uptake
protocol, the implants were washed in PBS for up to 7 days to avoid leaching of MnTnOct-2-PyP
from the BP sample. The animals were sacrificed at 90 days and the explanted BP samples were
processed for either paraffin embedding, acid hydrolysis, or the NBT assay. Paraffin embedding
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was performed following fixation in neutral buffered formalin. Acid hydrolysis was performed on
lyophilized tissues for calcium quantification. The NBT assay was done as previously described
with 4 mm sections.
Sheep patch implants
Sheep patch surgeries were done in collaboration with Professor Richard Bianco and
colleagues in the Department of Surgery at the University of Minnesota. Two loading doses of
MnTnOct-2-PyP were used to determine the effective dose range for MnTnOct-2-PyP. Either 15
µg or 150 µg MnTnOct-2-PyP was added to 1 cm2 BP sections for low and high doses, respectively.
Loaded samples were then washed for up to 7 days in PBS prior to implantation. The patches
were also washed in 4% paraformaldehyde for sterilization. Six BP patches, either control or
MnTnOct-2-PyP loaded were sewn into the walls of the aorta, left atrium, or pulmonary artery of
each sheep. Previous studies have used similar patch models for exposing BHV materials to blood
flow [71, 135]. In the left atrium and aorta, 1 control and 1 high dose MnTnOct-2-PyP patches were
placed at each site. In the pulmonary artery, 1 control and 1 low dose MnTnOct-2-PyP patches
were placed. A total of 4 sheep were included in this study. After 90 days, the animals were
sacrificed and the patches were removed en bloc. The primary endpoint for analysis was oxidized
amino acid quantification, which was performed on paraffin sections. Remaining tissue was acid
hydrolyzed for calcium quantification. The NBT assay was performed on only the aortic patches
from 2 animals due to the availability of explanted tissue.
Liposome preparation and characterization
For proof of principle studies with a targeted liposomal drug delivery system and MnPyP,
liposomes were conjugated to an endothelial antibody, platelet endothelial cell adhesion molecule
(PECAM), for formulation studies with SOD mimetics, through collaboration with Vladimir
Muzykantov, Melissa Howard, and Elizabeth Hood at the University of Pennsylvania. The PECAM
antibody was thiolated with SATA for covalent interaction with maleimide, which was introduced
into the lipid bilayer as DSPE-PEG-maleimide, thereby also providing a PEG linker. Liposomes
were prepared by dehydration and extrusion. Briefly, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine
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(DPPC), 1-hexadecanoyl-sn-glycero-3-phosphocholine (PC), L-α-phosphatidylglycerol (PG),
cholesterol,

and

1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide(polyethylene

glycol)-2000] (ammonium salt) (DSPE-PEG(2k)-maleimide) in chloroform were combined for a
molar ratio of 4.47:2.16:1.00:1.34:0.38:0.1 as previously described [129, 130]. The lipid solution
was dehydrated overnight, leaving a solid lipid film. The film was resuspended through shaking in
an aqueous solution of MnTnOct-2-PyP. The rehydrated, drug-containing films, were subject to
three cycles of freeze-thawing to improve drug loading efficiency.

The lipid films were then

extruded 10 times through 200 nm filters using an Avanti mini extruder to generate uni-lamellar
liposomes. Rat IgG and PECAM antibodies were thiolated with N-Succinimidyl S-Acetylthioacetate
(SATA) then added to the lipid films afer extrusion.

The liposomes were purified by

ultracentrifugation and resuspended in PBS. To determine antibody conjugation efficiency, 10%
I125 labeled-IgG was added to liposome preparations for quantification with a gamma counter; this
small percent of radiolabeled antibody was used to avoid false positives from unbound antibodies.
Size and polydispersity of the liposomes was assessed with dynamic light scattering. Loading
efficiency of MnTnOct-2-PyP was determined both by A455 by disrupting the liposomes in 1%
Triton X-100 as well as by SOD activity with the cytochrome c assay. Liposomes were tested intact
and disrupted (with 1% Triton X-100) to measure SOD activity by the cytochrome c reduction assay
(Fig. 4.1) as previously described [136, 137]. A reaction buffer consisting of xanthine (59 µM),
cytochrome c (23.5 µM), 50 mM potassium phosphate,100 µM EDTA, pH 7.8 was added to the
liposome samples. To initiate the production of superoxide, xanthine oxidase was added to all
samples. Absorbance at 550 nm was monitored for the reduction of cytochrome c (Fe 3+) to
cytochrome c (Fe2+), which absorbs at 550 nm.
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Fig. 4.2 Cytochrome c reduction assay. The reaction of xanthine oxidase with xanthine produces
superoxide as well as uric acid and hydrogen peroxide. Cytochrome c (Fe 3+) is reduced to
cytochrome c (Fe2+) in the presence of superoxide. When superoxide dismutase or SOD mimetics
are present, cytochrome c (Fe3+) is not reduced to cytochrome c (Fe2+) since SOD dismutates
superoxide to oxygen and hydrogen peroxide.
Targeting of the PECAM-liposomes was compared to the IgG-liposomes by incubating the
liposomes with PECAM-expressing cells, human umbilical vein endothelial cells (HUVEC). Cells
were blocked with 3% bovine serum albumin before adding the liposomes. Liposomes were left
on the cells for 30 minutes. Liposome binding was assessed by gamma counting of I 125 in the cell
pellet as compared to the supernatant.
4.4 Results
Characterization of SOD mimetics
Since the analysis of the MnPyP relied heavily on their quantification from absorbance,
both the structures and absorbance spectra of MnTE-2-PyP, MnTnOct-2-PyP, and MnTnOct-3-PyP
are shown in Fig. 4.3A-D. The compounds display a maximum spectral peak between 455 and
460 nm, whose intensity is dependent on the concentration of compound (Fig. 4.3D). Absorbance
at the spectral peak can be used to determine the concentration of the compound in solution from
a standard curve (Fig. 4.3E).
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Figure 4.3 Characterization of MnPyP. (A) MnTE-2-PyP, (B) MnTnOct-2-PyP, (C) MnTnOct-3PyP. (D) Spectra for each compound at 12.5 µM. (E) Standard curve for each compound of
absorbance at maximum wavelength vs. concentration.
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Uptake of Mn porphyrins in BP
To determine whether the MnPyP SOD mimetics could be incorporated in BP without an
active reaction such as a covalent modification and to identify the MnPyP SOD mimetic with the
greatest uptake, BP sections were incubated in each of the three compounds and uptake was
assessed 24 hours later with A455 or A460. For comparing MnTE-2-PyP and MnTnOct-2-PyP,
32.5 µg of compound was added to the BP sections. The uptake of MnTE-2-PyP was 29% of the
amount added or 9.4 µg whereas 77% or 24.9 µg of MnTnOct-2-PyP was taken up by BP (Fig.
4.4A). Since the major difference between the two compounds is the length of the alkyl chain,
these results suggest that the longer alkyl chain of MnTnOct-2-PyP facilitates greater uptake in BP.
In order to assess the effect the position of the substituted alkyl chain (meta or ortho) on
the uptake of an MnPyP SOD mimetic to BP, MnTnOct-3-PyP (meta) and MnTnOct-2-PyP (ortho)
were compared. MnTnOct-3-PyP had higher uptake than MnTnOct-2-PyP at the three loading
doses tested, but this difference was only significant at the highest dose (200 µg) and not the lower
loading doses (50 µg and 100 µg) (Fig. 4.4B). The percent uptake for both compounds, a measure
of uptake efficiency, decreased with the increasing loading dose (Fig. 4.4B). This suggests that
there may be a saturation point for loading MnPyP compounds in BP. Together, these results
demonstrate that the meta substituted MnPyP MnTnOct-3-PyP has higher uptake than MnTnOct2-PyP, but the uptake of both of these compounds does not increase linearly with an increase in
loading dose.
Since it was observed that an increase in loading dose does not correspond to a linear
increase in MnPyP uptake, higher doses of MnTnOct-3-PyP, which had the highest uptake of the
three compounds tested, were added to BP to identify the saturation point of uptake as well as to
assess whether it would be possible to add 10x more MnTnOct-3-PyP than MnTnOct-2-PyP to
account for the 10x lower SOD potency.

With increasing amounts of MnTnOct-3-PyP, a

significantly lower percent of compound is taken up by BP (Fig. 4.4C). The loading efficiency
significantly decreases over the range of 200-1300 µg with the maximum uptake being 300 µg,
which requires the 1300 µg loading dose (Fig. 4.4C). Based on the inefficiency of uptake at these
high loading doses, it would be optimal to use a lower starting dose, between 100 and 200 µg in
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order to maximize the uptake without wasting a significant amount of compound. For MnTnOct-2PyP, approximately 75% of the compound is taken up at both the 100 and 200 µg, thereby providing
high doses of MnTnOct-2-PyP in BP while conserving the amount of compound added to BP (Fig.
4.4B). These results indicate that the octyl substituted MnPyP have higher uptake into BP than
MnTE-2-PyP. Since the ortho substituted MnPyP SOD mimetics have 10x the SOD activity than
the meta substituted as determined by the rate constant for SOD dismutation, MnTnOct-2-PyP has
been identified as the best candidate for use with BHV.
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Figure 4.4 Uptake of MnPyP compounds in BP. (A) Ethyl vs octyl ortho analogues, 32.5 ug
added, % uptake noted at each column. (B) Meta vs. ortho octyl analogues compared at three
doses, 50, 100, or 200 ug, % uptake noted at each column. (C) High loading dose uptake of
MnTnOct-3-PyP, % uptake noted at each column. * p<0.05 between compounds.
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Stable incorporation of MnTnOct-2-PyP
Initial experiments with all three MnPyP SOD mimetics demonstrated that the compounds
are taken up by BP without an active or driven reaction. However, these experiments did not
address whether the compounds will remain retained in BP. Since MnTnOct-2-PyP was identified
as the best candidate for use with BP, additional experiments were performed to assess the stability
of the compound within BP. After an overnight incubation of either 50, 100, or 200 µg MnTnOct2-PyP with BP at 37 °C with shaking, the BP samples were placed in 5 mL PBS at 37 °C with
shaking to determine whether the compound was released from BP. The PBS solutions were
changed frequently to avoid saturation of the solution. A 7 day release period resulted in a plateau
of the release of MnTnOct-2-PyP from BP, thereby indicating that the compound retained in BP
was stable (Fig. 4.5A). These results demonstrate that MnPyP SOD mimetics are retained in BP
following the initial uptake stage and a prolonged release period.
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Fig. 4.5 Optimization of passive incorporation of MnTnOct-2-PyP. (A) Release of MnTnOct-2PyP from BP at different loading concentrations (B) Uptake, total release, and MnTnOct-2-PyP
retained in BP.
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SOD activity of drug loaded BP
In addition to stable retention of MnTnOct-2-PyP in BP, the compound must still mimic
SOD; therefore the SOD activity of drug loaded-BP was determined. The NBT reduction assay
rather than the cytochrome c assay was used due to interference from BP with the kinetic A550
monitoring used with the cytochrome c assay. The NBT reduction assay uses the same reaction
as cytochrome c to produce superoxide, but does not rely on the kinetics of the reduction of the
reporter molecular. A specific concern with using NBT with MnTnOct-2-PyP loaded BP is the fact
that high doses result in a color change of the tissue similar to the color of reduced NBT or NBTformazan dye. Therefore, a low dose of MnTnOct-2-PyP (loading dose of 10 µg/8 mm tissue) was
used to test the SOD activity of MnTnOct-2-PyP after incorporation into BP. NBT reduction was
mitigated in BP loaded with MnTnOct-2-PyP as compared to non-drug loaded BP (Fig. 4.6A). The
difference in NBT color change was analyzed in ImageJ by quantifying the mean gray value and
normalized to the mean gray value of the same tissues prior to reacting with NBT (Fig. 4.6). These
results demonstrate that MnTnOct-2-PyP retains SOD activity when incorporated in BP.
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Fig. 4.6 SOD activity of BP loaded with MnTnOct-2-PyP. (A) MnTnOct-2-PyP BP reacted with
xanthine oxidase/xanthine with or without NBT pre-incubation (B) Quantification of mean gray value
from image analysis in ImageJ.
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Rat subdermal implants of MnTnOct-2-PyP loaded BP
Rat subdermal implants of MnTnOct-2-PyP loaded BP were carried out for 90 days to
determine whether MnTnOct-2-PyP retains SOD activity as well as its effect on calcification and
dityrosine formation. MnTnOct-2-PyP loaded BP samples were prepared with a loading dose of
150 µg; following uptake and release approximately 70 µg MnTnOct-2-PyP were retained in the BP
samples used for implantation (Fig. 4.7A). Each rat had a non-drug loaded and MnTnOct-2-PyP
loaded BP sample to provide individual controls. The explanted BP samples were analyzed by the
NBT assay to determine whether MnTnOct-2-PyP retained SOD activity following subdermal
implantation. Compared to the non-drug loaded BP explants, the MnTnOct-2-PyP loaded BP
explants had significantly less reduction of NBT (Fig. 4.7B), thereby demonstrating that MnTnOct2-PyP loaded BP retains its activity following 90 day rat subdermal implantation.
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Fig. 4.7 Rat subdermal explants preparation and SOD activity. (A) Preparation of MnTnOct-2PyP loaded BP for implantation. (B) NBT assay with 90 day BP explants, MnTnOct-2-PyP and nondrug loaded. *p<0.05 vs non-drug loaded.
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The effect of MnTnOct-2-PyP on calcification of the 90 day rat subdermal implants was
assessed since calcium accumulation contributes to BHV degradation. In addition to unmodified
BP controls, BP that was exposed to pH 6.5, the pH of the MnTnOct-2-PyP loading solution, was
included to control for potential effects of the process of drug incorporation on BHV degradation.
The 90 day BP explants had mean calcium accumulation of 309.8 ± 18.4 µg calcium/mg tissue
(Fig. 4.8). MnTnOct-2-PyP loaded BP had less calcium accumulation than non-drug loaded BP
explants with a mean of 267.8 ± 23.7 µg calcium/mg tissue (Fig. 4.8). Surprisingly, the pH control
had significantly less calcium than both the non-drug loaded and MnTnOct-2-PyP loaded samples
with a mean of 119.9 ± 28.9 µg calcium/mg tissue (Fig. 4.8). Acidic conditions are necessary to
extract calcium from tissues therefore it may be that this slightly acidic pH interfered with the
initiation of calcium phosphate formation [138]. It was expected that the SOD mimetic could
decrease calcification since oxidation has been shown to promote calcification in certain situations
such as vascular calcification or atherosclerosis [139-141]. However, the effect of MnTnOct-2-PyP
on calcification was very modest.

Fig. 4.8 Calcification of rat subdermal explants loaded with MnTnOct-2-PyP. 90 day BP
explants control (unmodified), MnTnOct-2-PyP, and pH 6.5 control. *p<0.05 vs both control and
MnTnOct-2-PyP by one-way ANOVA with Tukey’s test.

102

Sheep patches of MnTnOct-2-PyP loaded BP
In order to assess MnTnOct-2-PyP loaded BP samples in an animal model that provides
both exposure to blood flow and mechanical (shear) stress, a sheep implant model was performed
through collaboration with Professor Richard Bianco of the University of Minnesota. A total of 4
juvenile sheep and 24 BP patches were used in this experiment. BP samples were sewn into the
walls at three locations in the heart: ascending aorta, pulmonary artery, and left atrium. Two BP
patches, both non-drug loaded and MnTnOct-2-PyP loaded, were placed at each location and
retrieved after 90 days. At the end of the study, all 24 patches were intact and later successfully
removed from the surrounding tissue (Fig. 4.9).

Fig. 4.9. Gross anatomy of sheep patch implants. (A) Distal ascending aorta. (B) Ascending
aorta. (C) Pulmonary artery. (D) Left atrium. Patches identified with arrows.
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Two doses of MnTnOct-2-PyP were analyzed in order to determine a dose range for activity
of MnTnOct-2-PyP towards oxidative and calcific damage. The low dose was prepared by adding
15 µg whereas the high dose was prepared with 150 µg MnTnOct-2-PyP. Following uptake and
release, 11 µg and 70 µg MnTnOct-2-PyP were retained in the low and high dose samples,
respectively (Fig. 4.10A). The SOD activity of non-implanted and explanted patches was assessed
by the NBT assay to determine whether exposure to circulation in the sheep model reduced SOD
activity of the MnTnOct-2-PyP loaded BP samples. Due to the availability of explanted material,
only 2 control and 2 MnTnOct-2-PyP loaded explants from the aortic position were analyzed. The
MnTnOct-2-PyP loaded explants had a lower, but statistically insignificant, fold change in mean
gray value, which suggests that the SOD activity of MnTnOct-2-PyP is retained (Fig. 4.10B). A
larger sample size is necessary to determine statistical significance; however, these results are
encouraging in that MnTnOct-2-PyP seems to retain SOD activity after in vivo exposure.
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Fig. 4.10. Sheep patch implants preparation and SOD activity. (A) Preparation of low and high
dose MnTnOct-2-PyP BP patches. (B) SOD activity as determined by the NBT assay of nonimplanted and explanted patches; n=2 for explanted samples, aortic patches from animals CAV3
and CAV4.
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Since BHV calcification is an important mechanism of BHV failure, calcium and
phosphorus, which comprise the calcium phosphate deposits, were quantified in the sheep patch
explants. Both calcium and phosphorus levels were close to the non-implanted levels (3.57 µg
calcium/mg tissue and about 0 phosphorus) for all but two patch explants (Fig, 4.11A). In one
animal (“CAV2”), the calcium levels of two drug loaded patches were much higher than all other
patches, but this was not seen in patches from any of the other three animals. Mean calcium levels
were highest in the left atrial patches (Fig, 4.11B) whereas mean phosphorus was highest in the
pulmonary artery patches (Fig. 4.11C), but with high variation. This result is not surprising due to
the short implantation period. The duration of 90 days was chosen since the primary end point of
interest was oxidation rather than calcification and previous studies with catheter-deployed BJV
BHV in the pulmonary arteries demonstrated elevated dityrosine after only 90 days (Fig. 2.16).
These results therefore demonstrate low calcium and phosphorus accumulation in the sheep patch
implant model and no significant effect of MnTnOct-2-PyP.
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Fig. 4.11 Calcification of sheep patch explants loaded with MnTnOct-2-PyP. (A) Calcium and
phosphorus values for individual patches and samples; CAV1-4 indicate the individual animals. (B)
Mean calcium levels by patch location. (C) Mean phosphorus levels by patch location. Ao: aorta,
LA: left atrium, PA: pulmonary artery, “--”: control, “+”: MnTnOct-2-PyP.
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Liposomal delivery of SOD mimetics
Studies with the MnPyP SOD mimetics and BP demonstrated that these compounds
readily partition into tissue primarily through hydrophobic interactions since the octyl substituted
compounds have higher uptake than the ethyl substituted. In order to determine whether these
compounds would be useful in a targeted delivery application, antibody-conjugated liposomes,
MnTnOct-2-PyP-loaded liposomes were prepared (Fig. 4.12).

Fig. 4.12 MnPyP SOD mimetic antibody-conjugated liposomes. MnPyP SOD mimetics were
loaded in the aqueous core created by the lipid bilayer. Maleimide-SATA modified antibody
(PECAM) will be used to conjugate the antibody to the surface of the liposome.
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MnTnOct-2-PyP was chosen over MnTE-2-PyP and MnTnOct-3-PyP based on its high
partitioning efficiency in BP and potent SOD activity. Drug encapsulation efficiency, liposome size,
and antibody binding were determined for MnTnOct-2-PyP liposomes (Table 4.1). The drug loading
efficiency is high with approximately 70%, as determined by A455. The antibody binding was lower
than previously described, but could be due to procedural differences rather than the presence of
MnTnOct-2-PyP [129]. The size of the liposomes corresponds with previous formulations of these
liposomes containing other drug cargo [129, 130]. These results demonstrate that MnTnOct-2-PyP
is efficiently encapsulated in liposomes conjugated with antibodies for targeted delivery.

Table 4.1 MnTnOct-2-PyP liposome formulation. Both PECAM and IgG liposomes were
prepared containing MnTnOct-2-PyP. Drug loading, antibody binding, and liposome size were
assessed to characterize the liposomes.
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Targeting of the PECAM-conjugated liposomes to HUVECs was done to determine
whether the PECAM-conjugated liposomes are still able to bind endothelial cells with MnTnOct-2PyP as the drug cargo. More PECAM conjugated liposomes were bound to HUVECs than IgG
conjugated liposomes, demonstrating liposome targeting specific to endothelial cells through the
PECAM antibody (Fig. 4.13). This result demonstrates that there is PECAM antibody binding to
endothelial cells for liposomes loaded with MnTnOct-2-PyP.

Fig. 4.13 Binding of PECAM and IgG liposomes to HUVEC. Liposomes loaded with MnTnOct2-PyP and conjugated to either IgG or PECAM antibodies were incubated with HUVECs to
determine targeting of PECAM for cell binding.
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The SOD activity of the MnTnOct-2-PyP antibody-conjugated liposomes was determined
with the cytochrome c reduction assay in order to demonstrate that MnTnOct-2-PyP retains its SOD
activity after encapsulation. SOD activity was assessed in both intact as well as Triton-disrupted
liposomes to determine whether the liposome must be degraded for MnTnOct-2-PyP to have
activity. Cytochrome c reduction by superoxide was monitored by absorbance at 550 nm over 250
seconds (Fig. 4.14A). SOD activity was calculated from the curves in Fig. 4.14A by determining
the slope of the linear region (Fig. 4.14B), which can be converted to units of SOD activity per mL
of liposome preparation. The disrupted liposomes have more SOD activity as would be expected
if MnTnOct-2-PyP is loaded in the aqueous core; however, the intact liposomes also had SOD
activity, which suggests that some of the MnTnOct-2-PyP is loaded in the lipid bilayer. These
results demonstrate that both the intact and disrupted MnTnOct-2-PyP liposomes maintain SOD
activity, but degradation of the liposomes or release of the drug cargo results in the highest activity.
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Fig. 4.14 SOD activity of MnTnOct-2-PyP PECAM and IgG conjugated liposomes. (A) Time
course of cytochrome c reduction by superoxide generated from xanthine/xanthine oxidase in the
presence of intact or 1% Triton X-100 disrupted liposomes. (B) Quantification of SOD activity from
slope of time course.
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4.5 Discussion
MnPyP SOD mimetics are good candidates for mitigating oxidative damage of a long-term
implant such as BHV due to efficient partitioning into the BHV material BP and potent catalytic
antioxidant activity. Three MnPyP SOD mimetics were selected for potential use with BHV in order
to determine whether the length or position (meta vs ortho) of the alkyl chain affected uptake into
BHV materials.

Longer meta-substituted alkyl chains were shown to be most efficiently

incorporated into BP. However, the meta-substituted compounds have 10-fold lower SOD activity,
which could not be compensated for by loading more compound into BP. Therefore, MnTnOct-2PyP (ortho substituted octyl) was identified as the lead candidate for an SOD mimetic drug delivery
strategy for BHV. MnTnOct-2-PyP retained SOD activity following incorporation in BP. MnTnOct2-PyP loaded BP was tested in two animal models, both the rat subdermal implant model of
calcification and a sheep patch implant model that provided exposure to blood flow. MnTnOct-2PyP did not affect calcification of the implanted materials, but did retain SOD activity following
implantation. These studies demonstrate that the use of a MnPyP SOD mimetic, MnTnOct-2-PyP,
provides a simple method of drug delivery and may attenuate BHV oxidation.
Numerous studies have focused on the structure-function relationships of MnPyP SOD
mimetics, therefore MnTE-2-PyP, MnTnOct-2-PyP, and MnTnOct-3-PyP were specifically selected
as a group for optimization in delivery to BHV materials. The ortho-substituted compounds (MnTE2-PyP and MnTnOct-2-PyP) have the most favorable electrostatic and SOD activity based on the
reduction potential of the manganese center as well as the catalytic rate constant for superoxide
dismutation [61, 132].

However, it was expected that the more important characteristic for

incorporation would be lipophilicity or potential hydrophobic interactions. Both MnTnOct-2-PyP and
MnTnOct-3-PyP are significantly more lipophilic than MnTE-2-PyP. MnTnOct-3-PyP, the meta
analogue, has been shown to be more lipophilic and have more conformational flexibility than the
ortho analogue, which results in greater cellular accumulation [142].

In these studies, the

differences in incorporation efficiencies of the meta and ortho analogues was only evident at very
high concentrations where the maximum drug loading capacity was met. By comparing the three
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compounds, we concluded that the incorporation is likely due to hydrophobic interactions,
potentially through hydrogen bond formation between the octyl side chains and collagen. Our
findings that the efficiency of uptake into BP increased from MnTE-2-PyP to MnTnOct-2-PyP to the
highest with MnTnOct-3-PyP was not surprising. However, it would only be advantageous to use
MnTnOct-3-PyP over MnTnOct-2-PyP if the uptake was 10x greater to account for differences in
SOD activity. Interestingly, there is a saturation point for MnPyP uptake into BP, which appears to
be around 300 µg/8 mm BP section, but additional studies and replicates, which would require
significant amounts of the compounds, would be necessary to specifically identify this point. Thus,
MnTnOct-2-PyP was selected as the optimal candidate for incorporation into BHV materials due to
its efficient uptake and potent SOD activity.
Although MnPyP SOD mimetics are taken up by BP, all is not stably retained in the tissue
as determined by the release of compound into PBS. After determining that the compound
released from BP plateaus after 5-7 days, this step was added prior to any additional experiments,
particularly the rat and sheep models. Even with the release period, up to 40% of the compound
originally added to BP is retained. Based on the potency of the activity of these compounds as well
as the local delivery to the material since the compound is present at the site of oxidant production
or attack, we predict that this strategy would provide significant protection for BHV materials from
oxidation.
It was not expected that the incorporation of MnTnOct-2-PyP into BP would affect its SOD
activity since this was a passive process; however, SOD activity was confirmed to address this
potential issue. Determining SOD activity in a drug-loaded tissue was challenging since traditional
SOD activity assays could not be used due to the nature of the sample. The cytochrome c reduction
assay relies on spectrophotometric measurements on a short (less than 1 minute) time scale; the
presence of the tissue interfered with these measurements and was therefore unreliable. It was not
possible to quantify the SOD activity in terms of the catalytic rate constant in the NBT assay since
this assay uses an endpoint measurement rather than kinetics. Therefore, it was only possible to
demonstrate that the MnTnOct-2-PyP loaded BP tissues did have SOD activity in that there was
less NBT reduction as compared to the non-drug loaded samples. Additional studies could address
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methods to quantify the activity of the compounds after incorporation in order to determine if the
activity is affected. An additional unknown is the amount of compound that needs to be loaded into
the BHV material to effectively interfere with material oxidation.
Earlier studies with the DBP modification and rat subdermal implant model demonstrated
only modest oxidation of BHV as measured by the formation of dityrosine, thereby indicating that
this model does not fully represent BHV oxidation since it does not produce dityrosine levels
corresponding with clinical or sheep explants. However, this model is useful in assessing BHV
calcification since it is accelerated. Oxidative stress has been shown to drive calcification in certain
situations such as vascular calcification [140] or atherosclerosis [87].

The clinical use of

antioxidants in atherosclerosis prevention has been studied based on this relationship. Therefore,
we hypothesized that in addition to mitigating BHV oxidative damage, an SOD mimetic may also
reduce calcification of BHV. In the previous studies with DBP it was not possible to directly assess
the effect of an antioxidant on BHV calcification since the DBP chemistry involves exposure to
ethanol, a known anti-calcification agent [88]. Calcification of MnTnOct-2-PyP rat subdermal
explants was surprisingly not significantly less than the unmodified explants and was actually higher
than the pH control, which was used at the same pH as MnTnOct-2-PyP. A possible explanation
for the apparent anti-calcification effect of the pH control is that if the slightly acidic pH (6.5) was
maintained during implantation, this could prevent calcium phosphate deposition since acids are
used to solubilize these crystals [138] It is still possible that an antioxidant could mitigate BHV
calcification, however, MnTnOct-2-PyP does not have this effect. A possible explanation for this
finding is that the specific antioxidant MnTnOct-2-PyP did not affect BHV calcification due to its
properties, in particular, the manganese center. Manganese supplementation is used to promote
bone health, which was based on early studies demonstrating a positive effect of manganese diet
supplementation on bone growth and strength [143]. Therefore, future work should directly address
the relationship between oxidation and calcification without the confounding variables of a specific
antioxidant.
Testing BHV leaflet materials in a large animal valve replacement model is expensive and
requires significant resources including surgical facilities, surgeons, and clinical-grade valves. The
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sheep patch implant model provides an alternative that still exposes the materials to blood and
mechanical stresses; two factors that are not represented in the rat subdermal implant model
However, the mechanical forces that the patches are exposed to are primarily shear whereas the
normal heart valves are exposed to additional including flow and flexural stresses [144]. This model
also allowed for testing a high number of samples per animal since multiple locations in the heart
could be used. It is likely that the short implant duration (90 days) was the major contributor to the
low levels of both calcium and phosphorus in the samples. Although MnTnOct-2-PyP did not affect
calcification in this model or in the rat model, a longer sheep calcification study should be performed
to ensure that MnTnOct-2-PyP does not accelerate calcification.
Dityrosine was selected as the endpoint for implant oxidation since it is present in clinical
BHV explants but not in non-implanted materials and potentially represents a functional effect of
BHV oxidation. Dityrosine cross-links could cause stiffening of the valve material, which may affect
mechanical properties. Quantification of dityrosine levels in the MnTnOct-2-PyP BP explants are
pending.
Liposomal formulations of MnTnOct-2-PyP were prepared to demonstrate that MnTnOct2-PyP is a good candidate for targeted liposomal delivery. In these studies, the liposomes were
conjugated to PECAM, which is used for targeting to the endothelium. However, there are many
possible applications for targeted delivery of MnPyP SOD mimetics including cancer chemo or
radiosensitizers [124, 145] and inflammation related to acute lung injury [127, 128]. The goals of
these studies were to provide proof of principle that MnPyP SOD mimetics could be delivered via
a liposomal system without affecting liposome structure or in this situation, antibody binding. The
use of liposomal delivery rather than systemic delivery of MnPyP has the potential to increase the
dose at the necessary site and to prevent toxicity related to off-target effects.
For most liposomal drug delivery systems, the drug cargo is loaded either into the aqueous
core or the lipophilic shell, depending on the water solubility of the particular drug [126, 146]. In
some instances, the drug cargo may load in both areas. It is interesting for the case of MnTnOct2-PyP liposomes that the intact carriers had significant SOD activity. It is expected that MnTnOct2-PyP would be localized to the aqueous core since it is a water soluble drug; however, as was
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demonstrated with BP, the alkyl chains are hydrophobic and could facilitate uptake into the lipophilic
shell of the liposomes. This could explain the efficient drug loading as well as the SOD activity of
the intact liposomes. In addition, having MnTnOct-2-PyP accessible from the surface of the
liposome could accelerate the action of the drug once it has reached the target site since the
liposomes do not require internalization and complete degradation for SOD activity. MnTnOct-2PyP loaded liposomes therefore represent an interesting possibility for targeted drug delivery given
the appropriate model or disease state.
In conclusion, we show that MnPyP SOD mimetics can be incorporated in BP, which is
likely mediated through hydrophobic interactions with the four alkyl substituents. These interactions
provide stable retention of the compound within the BHV material BP as well as in liposome drug
carriers. The compounds retain their SOD potency after incorporation and may therefore prevent
BHV oxidation in a sheep circulatory model.

These results suggest future investigations of

MnTnOct-2-PyP for preventing BHV oxidant-mediated degradation.
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Chapter 5: Conclusions and Future Directions

Improving BHV durability would address a significant clinical need since currently 30% of
BHV fail within 10 years of implantation [147] and the alternative, mechanical valves, require longterm anti-coagulation [1]. The primary aim of my dissertation was to explore the role of oxidative
stress in BHV degradation with an additional goal being the development of potential therapeutic
strategies targeting this process in an effort to improve BHV durability.
5.1 BHV susceptibility to oxidation
Through both the analysis of clinical BHV explants and the use of experimental systems of
BHV oxidation, we determined that BHV are susceptible to oxidation and that this process can lead
to material degeneration [102]. The major finding of our analysis of failed clinical BHV explants
was the elevation of the tyrosine oxidation product dityrosine in these explants and the absence in
non-implanted BHV materials. Tyrosyl radicals are formed through the oxidation of tyrosine by
various oxidants; the reaction of two tyrosyl radicals can then result in the formation of dityrosine
[78]. This is unlike many other oxidation products that involve a specific oxidation pathway, rather
than a range of oxidants, such as with chlorotyrosine which is a product of hypochlorous acid that
is produced by myeloperoxidase [148]. Dityrosine may also represent a functional effect of BHV
oxidation since it is a protein cross-link that could affect the material properties of BHV [83, 97,
149]. Additional studies are needed to determine the specific functional effect of this increase in
dityrosine in BHV, but based on these studies we have shown that dityrosine may be a marker of
BHV oxidation.
Since BHV degradation occurs on a time scale of years, it was necessary to use
accelerated experimental models to identify the structural effects of oxidation on BHV materials.
The H2O2/FeSO4 system, which was based on a model used to assess oxidative degradation of
polymers [65, 66], demonstrated that oxidation of BP results in a breakdown of glutaraldehyde
cross-links, an increase in susceptibility to digestion by collagenase, and disruption of the normal
collagen structure [102]. Each of these effects could have the result of material deterioration. An
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interesting finding from the H2O2/FeSO4 system was that glutaraldehyde cross-links are lost with
exposure to oxidizing conditions. A similar result using 3H-glutaraldehdye to cross-link BP was
reported from the rat subdermal implant model many years ago showing a significant loss
glutaraldehyde in 21 day explants [37]. This study suggested that the result was mostly due to
leaching of glutaraldehyde from BP, but with the 60% glutaraldehyde loss that was demonstrated,
it is possible that other active mechanisms such as oxidation were involved. Glutaraldehyde crosslinking is an important property of BHV as it provides stability against proteolytic degradation,
reduces immunogenicity, and improves mechanical properties [99].

It is possible that

glutaraldehyde could even provide protection against oxidation through the introduction of
additional cross-links.

However, since glutaraldehyde is also susceptible to oxidation, any

protection that would be conferred is likely transient since the glutaraldehyde cross-links are also
susceptible to oxidation.
In order to corroborate the findings from the H2O2/FeSO4 system with an in vivo system,
the rat subdermal implant model was initially utilized but demonstrated poor representation of these
endpoints, thereby suggesting that BHV oxidation may require both exposure to blood and
mechanical forces, which this models lacks. A significant challenge in the field of BHV is the
availability of animal models. The rat subdermal implant model has great value for the analysis of
calcification since it provides an accelerated and technically simple system. However, as we
learned with BHV oxidation, this system does not recapitulate other mechanisms of BHV
degradation, which is likely due to the lack of blood flow exposure. We hypothesized that BHV
oxidation would be represented in the rat model since the major source of ROS/RNS that is likely
to cause BHV oxidation is inflammatory cells. Despite demonstrating that there is an intense
inflammatory response to BHV materials in the rat subdermal implant model, BHV oxidation was
modest. Therefore, it is likely that other factors, particularly blood exposure, drive BHV oxidation.
Through our analysis of pulmonary artery, catheter-deployed BHV, we were able to determine that
a short-term circulatory animal model does have dityrosine accumulation; therefore supporting the
hypothesis that blood exposure is necessary for BHV oxidation. The sheep patch model used to
assess the SOD mimetics strategy was useful in providing a simplified system with blood exposure,
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but still required skilled surgeons and the expense of large animal care. Unfortunately, the use of
non-animal models, such as in vitro circulatory models like the Chandler loop [150], are not a viable
alternative due to the short-term nature and implant size constraints, which prevents the use of a
full sized BHV. An ideal system would allow for testing of full sized BHV under physiologic forces
and with exchange of blood flow for longer time points. Even with such a system, the gold standard
will still be large animal valve replacement models [70].
It is not unexpected that oxidative stress affects BHV and may contribute to degradation
since it was previously known that patients do have an inflammatory response to these devices
[21, 151, 152]. It has been long recognized that even materials that are considered the most
biocompatible still elicit a host response [24] and that this response can contribute to the
degradation or eventual failure of the device [27, 67]. The role of the foreign body response and in
particular oxidative stress has been very well characterized for the degradation of synthetic devices
and we aimed to apply those methods to this different class of device, tissue-based prosthetic heart
valves. Despite BHV being fabricated from non-synthetic materials, they are still foreign materials
since they are derived from porcine or bovine and, in addition, are cross-linked with glutaraldehyde
which is known to cause problems of its own including an exacerbation of BHV calcification. The
major question in this area was not whether there is a host response to BHV, but whether this
response then has any effect on the integrity of the material or function of the device. By identifying
dityrosine in clinical BHV explants we were able to demonstrate that BHV are oxidized, likely as a
result of inflammatory-produced ROS/RNS and the use of experimental models allowed for the
identification of some effects of oxidation on a glutaraldehyde fixed BHV material.
In addition to ROS/RNS, activated inflammatory cells produce proteases such as matrix
metalloproteinases (MMPs) that may be capable of degrading BHV [153]. Although glutaraldehyde
fixation provides resistance to proteolytic degradation prior to implantation [42], we have shown
that following implantation the materials become more susceptible to proteases. Therefore, MMPs
may also have a role in the degradation of BHV. The use of an anti-inflammatory compound could
mitigate BHV degradation by inhibiting the production of MMPs as well as ROS/RNS by reducing
the activation or migration of inflammatory cells or by directly targeting ROS/RNS enzymes such
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as NADPH oxidase [154]. With the antioxidant approach, the effects of ROS/RNS rather than their
production are inhibited. The concerns with using a general anti-inflammatory agent are the
systemic effects, but it may be possible to avoid these effects if the compound is immobilized within
the BHV materials similarly to DBP.
The use of BHV in children and adolescents remains a significant challenge to this day,
with reports of early failure still representing a major issue for the field [11, 155]. BHV in young
patients have more rapid BHV calcification [12], which may be due to differences in calcium
homeostasis or metabolism that drives this progression.

It is possible that there are also

differences in oxidation-mediated BHV leaflet deterioration based on age. Similarly, the general
inflammatory response to the BHV or other medical device may differ between children and adults.
A comparison of BHV oxidation and inflammation in children and adults could provide insight into
the nature of BHV oxidation and the role of other factors such as patient age. These studies could
help to address the need for improving BHV durability for both children and adults.
5.2 The DBP modification mitigates BHV oxidation in vitro
The first strategy we used for mitigating BHV oxidation was covalent modification of the
BHV material BP with an oxidant scavenger DBP. In this strategy we were able to demonstrate
that DBP could be efficiently immobilized to BP without affecting BP material properties or the
oxidant scavenging activity of DBP. Most importantly, DBP showed efficacy in the H 2O2/FeSO4
system in that DBP modified BP had significantly less oxidative damage as determined by the
previously identified endpoints. DBP was tested in the rat subdermal implant and was non-toxic as
well as anti-calcific. It is likely that the anti-calcification effects of DBP are due to the brief exposure
to ethanol [79] or the use of the carbodiimide-driven chemistry which may alter the cross-linking of
the material [39, 45]. Ideally DBP modified BP would have been tested in a circulatory animal
model where BHV oxidation may be better represented, but due to feasibility concerns as well as
a concern of the long-term efficacy of a stoichiometric antioxidant such as DBP, these studies were
not performed. The DBP modification strategy demonstrated proof-of-principle concepts that an
antioxidant may improve the durability of BHV by preventing oxidative damage, thereby providing
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a platform for future research in this area. Future studies should assess the behavior of DBP in
the heart valve position as well as the effect on oxidative and calcific BHV degradation.
DBP was selected for modification of BHV based on previous studies from the Levy lab
using similar BHT analogues [27]. Structure-function relationships were performed to identify the
best candidate compound for use an antioxidant modification of biomaterials, initially polyurethane
[36, 51]. Other common antioxidants such as α-tocopherol could not be used in place of DBP due
to the lack of necessary functional groups. It may be possible to develop an antioxidant that can
both be immobilized and have catalytic antioxidant activity in order to combine to the two features
offered separately from the DBP and SOD mimetic approaches, but this would require significant
time and expertise since to our knowledge, a compound with these characteristics is not
commercially available.
Since BHV are long-term implants, some types of drug delivery methods cannot be used.
In particular a strategy that involves drug release from the device, such as a drug-eluting stent,
would not be a good system for BHV since the total amount of drug that can be delivered over the
lifetime of the device is limited. For stents this is thought to be less of a concern since the drugs
are used to target the acute inflammatory phase which can result in rapid restenosis [156, 157].
For BHV, it is likely that they are exposed to ROS/RNS throughout the lifetime of the device either
through an active chronic inflammatory response to the device. Therefore, the amount of drug that
could be delivered through a mechanism similar to a drug-eluting stent would have severe
limitations in BHV applications. Similarly, intravenous delivery of drug carriers targeting the device,
if possible, would require numerous administrations and would not be a feasible option from a
patient convenience or cost perspective. The methods that have previously been used to provide
local drug delivery to BHV involved some type of covalent modification; either through residual
aldehyde groups [37] or through a modified version of the carbodiimide chemistry used to attach
DBP [39]. As long as the drug being delivered remains attached and active, these approaches do
have potential as clinical treatment. Unfortunately, many of the strategies that have been tested
were targeting calcification of BHV and did not show significant efficacy. However, since we are
targeting a different mechanism with DBP there is still promise for clinical efficacy.
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5.3 SOD mimetics may provide sustained protection against BHV oxidation
Although the DBP strategy did show efficacy in experimental models, we sought to develop
an improved strategy for mitigating BHV oxidation through the use of a catalytic antioxidant and the
exclusion of additional chemistry such as the carbodiimide-driven reaction used with DBP.
MnTnOct-2-PyP, a SOD mimetic, was efficiently incorporated into BP through passive interactions,
likely hydrophobic interactions involving the alkyl substituents. MnTnOct-2-PyP retained SOD
activity after incorporation. This strategy was tested in both the rat model and a sheep patch
implant model in order to provide exposure to blood flow.

MnTnOct-2-PyP did not affect

calcification in either model. A promising finding from both animal models is that MnTnOct-2-PyP
retained SOD activity after exposure to either a subdermal pouch or blood flow. This indicates that
MnTnOct-2-PyP may provide sustained antioxidant protection.
The effect of MnTnOct-2-PyP on oxidation will be determined through the quantification of
dityrosine, but these results are currently pending. We considered assessing other endpoints to
determine the effect of MnTnOct-2-PyP on oxidation, but were limited in the available explant
material as well as good alternative endpoints. Dityrosine is the best measure of oxidative stress
we have found for BHV. We examined many other potential endpoints including histology for
collagen damage, collagenase digestibility, and loss of collagen with hydroxyproline, but were only
able to correlate the dityrosine finding with clinical BHV explants. Dityrosine quantification has the
advantage in that it can be performed on paraffin-embedded sections, therefore other endpoints
such as histology can also be assessed, but requires an established mass spectrometry method.
An area of concern with the SOD mimetics passive incorporation strategy is the true
stability of this form of drug loading. Although we showed that after a 7 day release period the
release of compound from BP cannot be measured and that the drug-loaded rat and sheep explants
retain activity, the real test will be in a longer term valve replacement model where there are both
flexural and shear stresses. It is possible that the interactions between the MnPyP SOD mimetics
and the BHV leaflet materials are very stable, but this should be assessed in high flow model.
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5.4 Future directions
The DBP and MnTnOct-2-PyP strategies could both be viable therapeutic options since
they displayed different forms of efficacy. DBP significantly reduced BHV calcification and to a
greater degree than the currently used ethanol anti-calcification treatment which had breakthrough
calcification in the 90 day rat model [79, 88]. MnTnOct-2-PyP did not affect calcification, in a
positive or negative manner, and did retain SOD activity, but dityrosine results are pending.
Following the dityrosine results for the sheep patch model, the next step for both approaches is
assessment in a large animal sheep valve replacement model to determine the mechanical
properties as well as effect on degradation. It would be interesting to compare the durability of
DBP and MnTnOct-2-PyP modified BHV leaflets to determine which strategy has a greater effect
on overall BHV durability and performance.
Future studies should focus on identifying the specific factors that drive BHV oxidation in
addition to inflammation and exposure to blood flow. One area that we were not able to fully explore
was the time frame of oxidation. The foreign body reaction involves both acute and chronic
inflammation, therefore BHV may be exposed to inflammatory cell ROS/RNS production throughout
the lifetime of the device. However, it is also possible that more oxidative damage occurs in the
acute phase due to a more robust inflammatory response; therefore, it would only be necessary to
target this early stage rather than the entire lifetime of the device.
Since calcification remains a significant cause of BHV degradation, additional studies
should focus on disseminating the relationship between oxidation and calcification since we now
know that both processes do contribute to BHV degradation. We expect that oxidation would
accelerate calcification since this is seen in both native vascular (atherosclerosis) and valvular
calcification [140, 141, 158].

However, in these situations, the mechanism involves cellular

activation or transdifferentiation such as the phenotypic switch of valvular interstitial cells from
smooth muscle cells to pro-osteogenic cells in native aortic valve calcification [159, 160]. Since
BHV materials are non-vital due to the decellularization by glutaraldehyde, the effect of oxidation
on calcification may be a non-cellular mediated process or could involve inflammatory cells at the

124

material surface. It is also possible that oxidative and calcific degradation of BHV are not related.
Assessment of the localization of both calcification and oxidation could help to determine if these
processes are spatially related. For example, most calcification occurs on the circumferential edge
of a BHV [93] whereas collagen degradation occurs in the center of the leaflet [14]. Analysis of
clinical explants for dityrosine at the edge, circumferential, commissural, and center of explants
could determine the localization of BHV oxidation which may provide additional insight into the
relationship between oxidation and calcification.
Analysis of a larger set of clinical BHV explants could provide insight on the relationship
between the various types of BHV degradation. We did evaluate the correlation between factors
such as implant duration, dityrosine level, and calcification in our set of clinical BHV explants but
were unable to draw any conclusions due to the small sample size. With a larger sample set, these
relationships could be better studied with a greater statistical power.
BHV degradation is known to be caused by several mechanisms and the overlap of these
processes has not been fully elucidated (Fig. 5.1). BHV calcification is driven by numerous factors,
including serum calcium and phosphorous levels, alkaline phosphatase activity, and bone
remodeling proteins such as osteocalcin and osteopontin, which are affected by age and comorbidities such as renal failure [161]. Here we show that oxidation of BHV, likely resulting from
the production of ROS/RNS by inflammatory cells, results in dityrosine formation, loss of
glutaraldehyde cross-links, and increase in collagenase digestibility; all which may result in material
deterioration. Structural damage to BHV may also occur through mechanical forces such as shear
and flexural stresses [14]. Each of these processes may occur independently or influence each
other and the progression to BHV failure.
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Fig. 5.1 Pathways of BHV degradation. Calcification and mechanical stress were previously
known mechanisms of BHV degradation. Here we identified ROS/RNS oxidation of BHV as an
additional mechanism of degradation.
The results presented here support the hypothesis that oxidative stress contributes to BHV
degradation. Through modification of BHV materials with antioxidants, we show that this process
of degradation may be mitigated through pharmacologic methods, with the hope of improving BHV
durability.
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